<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic use of ergot alkaloids in the third stage of labour - Liabsuetrakul, T - 2018 | Cochrane Library</title> <meta content="Prophylactic use of ergot alkaloids in the third stage of labour - Liabsuetrakul, T - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005456.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic use of ergot alkaloids in the third stage of labour - Liabsuetrakul, T - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005456.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005456.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic use of ergot alkaloids in the third stage of labour" name="citation_title"/> <meta content="Tippawan Liabsuetrakul" name="citation_author"/> <meta content="Prince of Songkla University" name="citation_author_institution"/> <meta content="tippawan.l@psu.ac.th" name="citation_author_email"/> <meta content="Thanapan Choobun" name="citation_author"/> <meta content="Prince of Songkla University" name="citation_author_institution"/> <meta content="Krantarat Peeyananjarassri" name="citation_author"/> <meta content="Prince of Songkla University" name="citation_author_institution"/> <meta content="Q Monir Islam" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD005456.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/06/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005456.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005456.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005456.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Labor Stage, Third; Administration, Oral; Ergot Alkaloids [administration &amp; dosage, *therapeutic use]; Injections, Intramuscular; Injections, Intravenous; Postpartum Hemorrhage [*prevention &amp; control]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005456.pub3&amp;doi=10.1002/14651858.CD005456.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="mvgXlmVk";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005456\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005456\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ja","fr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005456.pub3",title:"Prophylactic use of ergot alkaloids in the third stage of labour",firstPublishedDate:"Jun 7, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005456.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005456.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005456.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005456.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005456.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005456.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005456.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005456.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005456.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005456.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4315 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005456.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-sec-0114"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-sec-0082"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-sec-0108"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/appendices#CD005456-sec-0119"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/table_n/CD005456StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/table_n/CD005456StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic use of ergot alkaloids in the third stage of labour</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information#CD005456-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Tippawan Liabsuetrakul</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information#CD005456-cr-0003">Thanapan Choobun</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information#CD005456-cr-0004">Krantarat Peeyananjarassri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information#CD005456-cr-0005">Q Monir Islam</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information/en#CD005456-sec-0124">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 June 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005456.pub3">https://doi.org/10.1002/14651858.CD005456.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005456-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005456-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005456-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005456-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005456-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005456-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005456-abs-0001" lang="en"> <section id="CD005456-sec-0001"> <h3 class="title" id="CD005456-sec-0001">Background</h3> <p>Previous research has shown that the prophylactic use of uterotonic agents in the third stage of labour reduces postpartum blood loss and moderate to severe postpartum haemorrhage (PPH). PPH is defined as a blood loss of 500 mL or more within 24 hours after birth. This is one of a series of systematic reviews assessing the effects of prophylactic use of uterotonic drugs; in this review prophylactic ergot alkaloids as a whole, and different regimens of administration of ergot alkaloids, are compared with no uterotonic agents. This is an update of a Cochrane Review which was first published in 2007 and last updated in 2011. </p> </section> <section id="CD005456-sec-0002"> <h3 class="title" id="CD005456-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of prophylactic use of ergot alkaloids in the third stage of labour by any route (intravenous (IV), intramuscular (IM), or oral) compared with no uterotonic agents, for the prevention of PPH. </p> </section> <section id="CD005456-sec-0003"> <h3 class="title" id="CD005456-sec-0003">Search methods</h3> <p>For this update, we searched the Cochrane Pregnancy and Childbirth Group's Trials Register, <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (19 September 2017); we also searched reference lists of retrieved studies. </p> </section> <section id="CD005456-sec-0004"> <h3 class="title" id="CD005456-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials or cluster‐randomised trials comparing prophylactic ergot alkaloids by any route (IV, IM, or oral) with no uterotonic agents in the third stage of labour among women giving birth vaginally. </p> </section> <section id="CD005456-sec-0005"> <h3 class="title" id="CD005456-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion, extracted data and checked them for accuracy; they also assessed the risk of bias in included studies. Two review authors assessed the quality of the evidence using the GRADE approach. </p> </section> <section id="CD005456-sec-0006"> <h3 class="title" id="CD005456-sec-0006">Main results</h3> <p>There were eight included studies: three studies had a low risk of bias and five studies had high risk of bias. The studies compared ergot alkaloids with no uterotonic agents, with a total of 2031 women in the ergot alkaloids group and 1978 women in the placebo or no treatment group. Seven studies used the IV/IM route of administration and one study used the oral route. </p> <p><b>Ergot alkaloids (any route of administration) versus no uterotonic agents</b> </p> <p>Use of ergot alkaloids in the third stage of labour decreased mean blood loss (mean difference (MD) ‐80.52 mL, 95% confidence interval (CI) ‐96.39 to ‐64.65 mL; women = 2718; studies = 3; moderate‐quality evidence); decreased PPH of at least 500 mL (average risk ratio (RR) 0.52, 95% CI 0.28 to 0.94; women = 3708; studies = 5; I<sup>2</sup> = 83%; low‐quality evidence); increased maternal haemoglobin concentration (g/dL) at 24 to 48 hours postpartum (MD 0.50 g/dL, 95% CI 0.38 to 0.62; women = 1429; studies = 1; moderate‐quality evidence); and decreased the use of therapeutic uterotonics (average RR 0.37, 95% CI 0.15 to 0.90; women = 2698; studies = 3; I<sup>2</sup> = 89%; low‐quality evidence). There were no clear differences between groups in severe PPH of at least 1000 mL (average RR 0.32, 95% CI 0.04 to 2.59; women = 1718; studies = 2; I<sup>2</sup> = 74%; very low‐quality evidence). The risk of retained placenta or manual removal of the placenta, or both, were inconsistent with high heterogeneity. Ergot alkaloids increased the risk of elevated blood pressure (average RR 2.60, 95% CI 1.03 to 6.57: women = 2559; studies = 3; low‐quality evidence) and pain after birth requiring analgesia (RR 2.53, 95% CI 1.34 to 4.78: women = 1429; studies = 1; moderate‐quality evidence) but there were no differences between groups in vomiting, nausea, headache or eclamptic fit. </p> <p>Results for IV/IM ergot alkaloids versus no uterotonic agents were similar to those for the main comparison of ergot alkaloids administered by any route, since most of the studies (seven of eight) used the IV/IM route. Only one small study (289 women) compared oral ergometrine with placebo and it showed no benefit of ergometrine over placebo. No maternal adverse effects were reported. </p> <p>None of the studies reported on any of our prespecified neonatal outcomes</p> </section> <section id="CD005456-sec-0007"> <h3 class="title" id="CD005456-sec-0007">Authors' conclusions</h3> <p>Prophylactic IM or IV injections of ergot alkaloids may be effective in reducing blood loss, reducing PPH (estimated blood loss of at least 500 mL), and increasing maternal haemoglobin. Ergot alkaloids may also decrease the use of therapeutic uterotonics, but adverse effects may include elevated blood pressure and pain after birth requiring analgesia. There were no differences between groups in terms of other adverse effects (vomiting, nausea, headache or eclamptic fit). There is a lack of evidence on the effects of ergot alkaloids on severe PPH, and retained or manual removal of placenta. There is also a lack of evidence on the oral route of administration of ergot alkaloids. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005456-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005456-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005456-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005456-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005456-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD005456-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005456-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005456-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005456-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005456-abs-0004" lang="en"> <h3>Managing the end of childbirth (placenta delivery) with ergot alkaloid medications (e.g. ergometrine) </h3> <p><b>What is the issue?</b> </p> <p>The third stage of labour is the period from the birth of the baby to the expulsion of the placenta and membranes. As the placenta separates, there is inevitably some blood loss from the placental site until the muscles of the uterus clamp the blood vessels. Fit, healthy women cope with this normal blood loss without problems, but where poor nutrition, poor sanitation and limited or no access to clinical care are complications of pregnancy, severe morbidity and death can result from excessive blood loss at birth. This is very common in low‐ and middle‐income countries. Active intervention, called 'active management of third stage', is recommended for the third stage of labour to reduce excess blood loss. Active intervention incorporates: 1) the administration of a uterotonic medication (medicine that stimulates contractions), given just before or just after the baby is born to help the muscles of the uterus contract; 2) cord clamping, performed approximately one to three minutes after birth; and 3) the use of controlled cord traction to deliver the placenta in settings where skilled birth attendants are available. This review of studies looked at the use of one group of uterotonic medications called ergot alkaloids (e.g. ergometrine) as part of this active management. </p> <p><b>Why is this important?</b> </p> <p>A previous systematic review showed that the combination of ergometrine and oxytocin was associated with a significantly lower postpartum haemorrhage (PPH) rate (defined as blood loss of at least 500 mL) but a greater incidence of side‐effects compared to the use of oxytocin alone. However, there was no review comparing ergometrine with no uterotonic medications and different routes or timings of administration for the prevention of PPH. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for evidence in September 2017 and included eight trials involving 4009 women receiving ergometrine by mouth (orally), into the muscle (intramuscularly (IM)) or into the vein (intravenously (IV)). Of eight trials, seven included studies were analysed in this updated review. </p> <p>The evidence from the trials analysed suggests that ergot alkaloids may decrease mean blood loss, increase maternal haemoglobin levels in the blood, and may decrease both blood loss of at least 500 mL (PPH) and the use of therapeutic uterotonics. It is uncertain whether ergot alkaloids have any effect on numbers of women experiencing high blood loss of at least 1000 mL (severe PPH). The evidence also suggested that they may increase adverse effects such as increased blood pressure and pain after birth. They may make little or no difference between groups in terms of other adverse effects (vomiting, nausea, headache or eclamptic fit) and results were inconsistent on the risk of retained or manual removal of placenta. Most of the evidence came from trials that administered ergot alkaloids using the IM or IV route. There was only one small trial that looked at the use of oral ergot alkaloids and results were inconclusive. There were limited numbers of included studies and results between studies were not always consistent or precise. Overall quality of evidence across critical and important outcomes ranged from very low to moderate. </p> <p><b>What does this mean?</b> </p> <p>The IV or IM route, although it may reduce blood loss and PPH, was associated with the adverse effects of raised blood pressure and pain due to contractions of the uterus. There was not enough evidence on the oral route of administering ergot alkaloids. There are other medications, namely oxytocin, syntometrine and prostaglandins (which are assessed in other Cochrane Reviews), that can be used and may be preferable. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005456-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005456-sec-0114"></div> <h3 class="title" id="CD005456-sec-0115">Implications for practice</h3> <section id="CD005456-sec-0115"> <p>Prophylactic intramuscular (IM) or intravenous (IV) injections of ergot alkaloids may be effective in reducing blood loss and postpartum haemorrhage (PPH) (estimated blood loss of at least 500 mL), and increasing maternal haemoglobin. They may also decrease the use of therapeutic uterotonics, but adverse effects may include elevated blood pressure and pain after birth requiring analgesia. There were no differences between use of ergot alkaloids and no uterotonics in terms of other adverse effects (vomiting, nausea, headache or eclamptic fit). There is a lack of evidence on the effects on severe PPH, retained or manual removal of the placenta and on the oral route of administering ergot alkaloids. </p> </section> <h3 class="title" id="CD005456-sec-0116">Implications for research</h3> <section id="CD005456-sec-0116"> <p>When ergot alkaloids were compared with no uterotonic agents, there was some evidence to suggest beneficial effects in terms of reduced postpartum blood loss and reduced use of additional therapeutic uterotonics, but higher risk of elevation of blood pressure. However, the participants in these trials were not at increased risk of PPH and so the possible benefits to this group of women have not really been assessed. The optimal dosing of, and route of administration for, ergot alkaloids is inconclusive and future trials could address this. The adverse effects of ergot alkaloids also need to be seriously considered. None of the studies on prophylactic use of uterotonics included in this review addressed neonatal outcomes or serious morbidity from PPH, thus there is the need in future trials to measure neonatal outcomes, serious morbidity in the mother and possible adverse effects of ergometrine on lactation. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005456-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005456-sec-0036"></div> <div class="table" id="CD005456-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ergot alkaloids (any route of administration) versus no uterotonic agents in the third stage of labour</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ergot alkaloids (any route of administration) versus no uterotonic agents in the third stage of labour</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Settings:</b> hospital settings in the USA, Ireland, and the Netherlands<br/> <b>Intervention:</b> ergot alkaloids (any route of administration) </p> <p><b>Comparison</b>: no uterotonic agents </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ergot alkaloids (any routes) and no uterotonic agents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean blood loss (mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss ranged across control groups from 234.8 to 520 mL</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss in the intervention groups was<br/> <b>80.52 mL lower</b><br/> (96.39 to 64.65 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2718<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>PPH (estimated or measured blood loss of at least 500 mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.52</b> <br/> (0.28 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3708<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><br/> (33 to 111) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/> (34 to 113) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Severe PPH (estimated or measured blood loss of at least 1000 mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.32</b> <br/> (0.04 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1718<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><br/> (1 to 80) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/> (3 to 166) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maternal haemoglobin concentration at 24 to 48 hours postpartum in the control group was 12.09 g/dL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maternal haemoglobin concentration at 24 to 48 hours postpartum in the intervention groups was<br/> <b>0.5 g/dL higher</b><br/> (0.38 to 0.62 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>1</sup><br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Use of therapeutic uterotonics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.37</b> <br/> (0.15 to 0.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2698<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b><br/> (20 to 119) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b><br/> (19 to 116) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Elevation of blood pressure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.6</b> <br/> (1.03 to 6.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2559<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b><br/> (137 to 874) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b><br/> (124 to 788) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Pain after birth requiring analgesia (not prespecified)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.53</b> <br/> (1.34 to 4.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<sup>1</sup><br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (24 to 86) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (24 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>PPH:</b> postpartum haemorrhage; <b>mL</b> : millilitre; <b>g/dL</b>: grams per decilitre </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Limitations in study design (‐1) </p> <p>2 Inconsistency of results, high I<sup>2</sup> value (‐1) </p> <p><sup>3</sup> Wide confidence interval crossing the line of no effect (‐1) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005456-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous/intramuscular ergot alkaloids versus no uterotonic agents in the third stage of labour</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous/intramuscular ergot alkaloids versus no uterotonic agents in the third stage of labour</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Settings:</b> hospital settings in USA and Ireland<br/> <b>Intervention:</b> intravenous/intramuscular ergot alkaloids </p> <p><b>Comparison</b>: no uterotonic agents </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous/intramuscular ergot alkaloids versus no uterotonic agents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean blood loss (mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss ranged across control groups from 234.8 to 325.9 mL</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss in the intervention groups was<br/> <b>81.75 mL lower</b><br/> (97.88 to 65.61 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2429<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Estimated or measured blood loss of at least 500 mL</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.41</b> <br/> (0.22 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3419<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/> (21 to 72) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (18 to 62) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Estimated or measured blood loss of at least 1000 mL</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.09</b> <br/> (0.01 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/> (0 to 11) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/> (0 to 11) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maternal haemoglobin concentration at 24 to 48 hours postpartum in the control group was 12.09 g/dL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maternal haemoglobin concentration at 24 to 48 hours postpartum in the intervention groups was<br/> <b>0.5 g/dL higher</b><br/> (0.38 to 0.62 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Use of therapeutic uterotonics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.25</b> <br/> (0.1 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2409<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><br/> (13 to 83) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b><br/> (13 to 83) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Elevation of blood pressure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.6</b> <br/> (1.03 to 6.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2559<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b><br/> (137 to 874) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b><br/> (124 to 788) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Pain after birth requiring analgesia (not prespecified)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.53</b> <br/> (1.34 to 4.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (24 to 86) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (24 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>PPH:</b> postpartum haemorrhage; <b>mL</b> : millilitre; <b>g/dL</b>: grams per decilitre </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Limitations in study design (‐1) </p> <p><sup>2</sup> Inconsistency of results, high I<sup>2</sup> value (‐1) </p> <p><sup>3</sup> Single study with few events (‐1) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005456-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral ergot alkaloids versus no uterotonic agents in the third stage of labour</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral ergot alkaloids versus no uterotonic agents in the third stage of labour</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Settings:</b> a single study, hospital setting in the Netherlands<br/> <b>Intervention:</b> oral ergot alkaloids </p> <p><b>Comparison</b>: no uterotonic agents </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral ergot alkaloids versus no uterotonic agents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean blood loss (mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss in the control group was 520 mL</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss in the intervention groups was<br/> <b>44 mL lower</b><br/> (132.08 lower to 44.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Estimated or measured blood loss of at least 500 mL</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.96</b> <br/> (0.72 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>289<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>385 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b><br/> (277 to 497) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>385 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b><br/> (277 to 497) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Estimated or measured blood loss of at least 1000 mL</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.36 to 1.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>289<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>112 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b><br/> (40 to 168) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>112 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b><br/> (40 to 168) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in the trial</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Use of therapeutic uterotonics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.79</b> <br/> (0.47 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>289<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/> (86 to 244) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/> (86 to 244) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Elevation of blood pressure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in the trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain after birth requiring analgesia (not prespecified)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in the trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>PPH:</b> postpartum haemorrhage; <b>mL</b> : millilitre; <b>g/dL</b>: grams per decilitre </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Single study with small sample size and wide confidence interval (‐2) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005456-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005456-sec-0037"></div> <section id="CD005456-sec-0038"> <h3 class="title" id="CD005456-sec-0038">Description of the condition</h3> <p>The third stage of labour is defined as the period of labour from birth of the baby to the expulsion or extraction of the placenta and membranes. Placental separation involves capillary haemorrhage and shearing of decidua spongiosa because of the mechanical action of uterine contraction. Blood loss during the third stage of labour depends on the time between placental separation and contraction of the placental bed by uterine activity. Most women experience mild to moderate blood loss. However, the third stage of labour can be a potentially hazardous period of childbirth resulting in postpartum haemorrhage (PPH). The World Health Organization (WHO) defines PPH as blood loss after delivery of 500 mL or more (<a href="./references#CD005456-bbs2-0100" title="World Health Organization. Managing Complications in Pregnancy and Childbirth: a Guide for Midwives and Doctors. Geneva: World Health Organization, 2000. ">WHO 2000</a>). </p> <p>In 2015, the estimate of global maternal mortality was approximately 303,000 (<a href="./references#CD005456-bbs2-0104" title="World Health Organization. Trends in Maternal Mortality:1990 to 2015 estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Geneva: World Health Organization, 2015. ">WHO 2015</a>). Almost all maternal deaths occur in low‐ and middle‐income countries. Unfortunately, due to socio‐economic conditions, dwindling investment in health, and non‐ or poorly‐functioning health systems, many women are unable to access essential care during pregnancy, childbirth and the postpartum period (<a href="./references#CD005456-bbs2-0073" title="AcuinCS , KhorGL , LiabsuetrakulT , AchadiEL , HtayTT , FirestoneR , et al. Maternal, neonatal, and child health in southeast Asia: towards greater regional collaboration. Lancet2011;377(9764):516‐25. ">Acuin 2010</a>). The most common preventable causes of maternal death are haemorrhage, pregnancy‐induced hypertension and sepsis. One of the most common causes of maternal death worldwide is PPH (<a href="./references#CD005456-bbs2-0092" title="SayL , ChouD , GemmillA , TunçalpÖ , MollerA , DanielsJ , et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health2014;2:e323–33. ">Say 2014</a>; <a href="./references#CD005456-bbs2-0089" title="McCormickML , SanghviHC , KinzieB , McIntoshN . Preventing postpartum hemorrhage in low‐resource settings. International Journal of Gynecology &amp; Obstetrics2002;77(3):267‐75. ">McCormick 2002</a>; <a href="./references#CD005456-bbs2-0101" title="World Health Organization. Maternal Mortality in 1995: Estimates Developed by WHO, UNICEF, UNFPA. Geneva: World Health Organization, 2001. ">WHO 2001</a>). </p> <p>Active management of the third stage of labour, before the occurrence of PPH, is better than treatment when blood loss is 500 mL or more. The third stage of labour is an important and critical period for interventions to reduce the incidence of PPH (<a href="./references#CD005456-bbs2-0078" title="DeGrootAN . Prevention of postpartum haemorrhage. Bailliere’s Clinical Obstetrics and Gynaecology1995;9(3):619‐31. ">De Groot 1995</a>). Active management involves prophylactic use of oxytocic drugs; umbilical cord clamping; and controlled cord traction for delivery of the placenta (<a href="./references#CD005456-bbs2-0102" title="World Health Organization. Pregnancy, Childbirth, Postpartum and Newborn Care: a Guide for Essential Practice. Geneva: World Health Organization, 2003. ">WHO 2003</a>). Three recommendations for active management in the third stage of labour are administration of an uterotonic drug within one minute of the birth of the baby, clamping and cutting the umbilical cord after birth, and delivering the placenta by applying controlled cord traction during a strong uterine contraction (<a href="./references#CD005456-bbs2-0081" title="DenHertogCE , DeGrootAN , VanDongenPW . History and use of oxytocics. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2001;94(1):8‐12. ">Den Hertog 2001</a>; <a href="./references#CD005456-bbs2-0089" title="McCormickML , SanghviHC , KinzieB , McIntoshN . Preventing postpartum hemorrhage in low‐resource settings. International Journal of Gynecology &amp; Obstetrics2002;77(3):267‐75. ">McCormick 2002</a>). Combined controlled cord traction in active management of the third stage reduces the time of the third stage, the incidence of PPH and retained placenta and the need for additional oxytocic agents compared with using only uterotonic drugs (<a href="./references#CD005456-bbs2-0077" title="BruckerMC . Management of the third stage of labor: an evidence‐based approach. Journal of Midwifery and Women's Health2001;46(6):381‐92. ">Brucker 2001</a>). Recent WHO recommendation suggests late cord clamping, in which the umbilical cord is clamped approximately one to three minutes after birth of the baby, and controlled cord traction is recommended in settings where skilled birth attendants are available (<a href="./references#CD005456-bbs2-0103" title="World Health Organization. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization, 2012. ">WHO 2012</a>). The recent updated Cochrane Review on active management of the third stage of labour showed a reduction of the incidence of severe blood loss and blood transfusion requirement but an increase in maternal blood pressure and pain, as well as reducing the baby's birthweight (<a href="./references#CD005456-bbs2-0075" title="BegleyCM , GyteGML , MurphyDJ , DevaneD , McDonaldSJ , McGuireW . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD007412.pub4] ">Begley 2015</a>). Likewise, the updated Cochrane Review on controlled cord traction for the third stage of labour found the reduction of blood loss and duration of the third stage of labour (<a href="./references#CD005456-bbs2-0087" title="HofmeyrGJ , MshweshweNT , GülmezogluAM . Controlled cord traction for the third stage of labour. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD008020.pub2] ">Hofmeyr 2015</a>). </p> </section> <section id="CD005456-sec-0039"> <h3 class="title" id="CD005456-sec-0039">Description of the intervention</h3> <p>Uterotonic agents are divided into three groups: ergot alkaloids, oxytocin and prostaglandins (<a href="./references#CD005456-bbs2-0080" title="DeGrootAN , VanDongenPW , VreeTB , HeksterYA , VanRoosmalenJ . Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs1998;56(4):523‐35. ">De Groot 1998</a>; <a href="./references#CD005456-bbs2-0081" title="DenHertogCE , DeGrootAN , VanDongenPW . History and use of oxytocics. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2001;94(1):8‐12. ">Den Hertog 2001</a>). Their mechanisms of preventing PPH are different. Methylergometrine is the most common type of ergot alkaloid; it increases the muscle tone of the uterus, with superimposed fast rhythmic contractions of the myometrium and tetanic contraction for several hours resulting in compressed myometrial blood vessels. Oxytocin acts through oxytocin receptors in myometrium and decidua, leading to fast and long‐lasting contractions upon basal tone of the myometrium. Syntometrine, consisting of five units of oxytocin and 0.5 mg of ergometrine, has been designed to take advantage of the rapid onset of action of oxytocin, combined with the longer action of ergometrine. Carbetocin is similar to oxytocin, but it has a rapid onset and prolonged duration of action relative to oxytocin. The effect of a room‐temperature stable formulation of carbetocin under the WHO CHAMPION Trial will be soon published (<a href="./references#CD005456-bbs2-0105" title="WidmerM , PiaggioG , Abdel‐AleemH , CarroliG , ChongYS , CoomarasamyA , et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trial2016;17(1):143. ">Widmer 2016</a>). Finally, prostaglandins induce strong myometrial contractions by increasing uterine tone (<a href="./references#CD005456-bbs2-0078" title="DeGrootAN . Prevention of postpartum haemorrhage. Bailliere’s Clinical Obstetrics and Gynaecology1995;9(3):619‐31. ">De Groot 1995</a>). There are several Cochrane systematic reviews already published about the use of various uterotonic drugs in the third stage of labour for preventing PPH (<a href="./references#CD005456-bbs2-0090" title="McDonaldS , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201.pub2] ">McDonald 2004</a>; <a href="./references#CD005456-bbs2-0093" title="SuLL , ChongYS , SamuelM . Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD005457.pub4] ">Su 2012</a>; <a href="./references#CD005456-bbs2-0096" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>; <a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>). </p> <p>Recent studies have highlighted oxytocin as the first‐line drug used for prophylaxis based on the evidence of its benefit in terms of reducing PPH compared with using no uterotonic drugs, and its favourable side‐effect profile (<a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>). However, the use of the combination preparation of ergot alkaloid plus oxytocin, syntometrine, is associated with a statistically significant reduction of PPH when compared with oxytocin alone, attributable to the ergometrine effect (<a href="./references#CD005456-bbs2-0090" title="McDonaldS , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201.pub2] ">McDonald 2004</a>). Because of the effect of strong and lasting uterine contractions, ergometrine has been used as one of the uterotonic drugs of choice for preventing PPH. </p> </section> <section id="CD005456-sec-0040"> <h3 class="title" id="CD005456-sec-0040">How the intervention might work</h3> <p>Ergometrine is ergot in origin and was recovered first as a product of a fungus, <i>Claviceps purpurea</i>, and used in obstetrics for the first time in 1582. This use ended in 1822 due to uterine rupture, stillbirth and maternal death from inaccurate doses and ergotism (gangrene and convulsive forms) (<a href="./references#CD005456-bbs2-0080" title="DeGrootAN , VanDongenPW , VreeTB , HeksterYA , VanRoosmalenJ . Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs1998;56(4):523‐35. ">De Groot 1998</a>; <a href="./references#CD005456-bbs2-0097" title="VanDongenPW , DeGrootAN . History of ergot alkaloids from ergotism to ergometrine. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1995;60(2):109‐16. ">Van Dongen 1995</a>). However, ergot alkaloids were found to be more useful and less harmful for obstetric practice in the form of ergometrine in 1932 by Moir and Dale (<a href="./references#CD005456-bbs2-0083" title="DunnPM . John Chassar Moir (1900‐1977) and the discovery of ergometrine. Archives of Diseases in Childhood. Fetal &amp; Neonatal Edition2002;87:F152‐4. ">Dunn 2002</a>). They have specific uterotonic action through adrenergic receptors with less vasoconstrictive ability, and they prevent excessive bleeding after childbirth. Two chemical ergot alkaloids are ergonovine/ergometrine maleate (ergotrate) and methylergonovine/methylergometrine maleate (methergine). They produce persistent uterine contractions in the inner zone of the myometrium through calcium channel mechanisms and actin‐myosin interaction, leading to the shearing effect on placental separation and less blood loss or PPH, but they may increase the risk of maternal side effects such as hypertension and other complications of vasoconstriction (<a href="./references#CD005456-bbs2-0077" title="BruckerMC . Management of the third stage of labor: an evidence‐based approach. Journal of Midwifery and Women's Health2001;46(6):381‐92. ">Brucker 2001</a>; <a href="./references#CD005456-bbs2-0080" title="DeGrootAN , VanDongenPW , VreeTB , HeksterYA , VanRoosmalenJ . Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs1998;56(4):523‐35. ">De Groot 1998</a>; <a href="./references#CD005456-bbs2-0082" title="DuaJA . Postpartum eclampsia associated with ergometrine maleate administration. British Journal of Obstetrics and Gynaecology1994;101(1):72‐3. ">Dua 1994</a>; <a href="./references#CD005456-bbs2-0085" title="GowriV , Al HinaiA . Postpartum second degree heart block induced by methergine. International Journal of Gynecology &amp; Obstetrics2003;81(2):227‐9. ">Gowri 2003</a>; <a href="./references#CD005456-bbs2-0094" title="SultatosLG . Mechanisms of drugs that affect uterine motility. Journal of Nurse‐Midwifery1997;42(4):367‐70. ">Sultatos 1997</a>; <a href="./references#CD005456-bbs2-0095" title="TaylorGJ , CohenB . Ergonovine‐induced coronary artery spasm and myocardial infarction after normal delivery. Obstetrics &amp; Gynecology1985;66(6):821‐2. ">Taylor 1985</a>). In addition, the risks of partial retention or trapping of the placenta (or both), manual removal of placenta, or uterine inversion or cord avulsion are still concerns with ergometrine administration (<a href="./references#CD005456-bbs2-0062" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52(6):694‐7. ">Sorbe 1978</a>). </p> <p>Different types of ergot alkaloid, and different routes and timing of administration, have been used for both prophylactic and therapeutic purposes (<a href="./references#CD005456-bbs2-0074" title="AndersenB , AndersenLL , SorensenT . Methylergometrine during the early puerperium; a prospective randomized double blind study. Acta Obstetricia et Gynecologica Scandinavica1998;77(1):54‐7. ">Andersen 1998</a>; <a href="./references#CD005456-bbs2-0076" title="BorriP , GerliP , AntignaniFL , BindiL , CozziC , MoscarellaG , et al. Methylergonovine maleate: a proposal for its more specific use. Biological Research in Pregnancy and Perinatology1986;7(3):128‐30. ">Borri 1986</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0044" title="MoirDD , AmoaAB . Ergometrine or oxytocin? Blood loss and side‐effects at spontaneous vertex delivery. British Journal of Anaesthesia1979;51:113‐7. ">Moir 1979</a>; <a href="./references#CD005456-bbs2-0098" title="VanSelmM , KanhaiHH , KeirseMJ . Preventing the recurrence of atonic postpartum hemorrhage: a double‐blind trial. Acta Obstetricia et Gynecologica Scandinavica1995;74(4):270‐4. ">Van Selm 1995</a>). The most common ergot alkaloids for obstetric treatment are ergometrine and methylergometrine. Both injectable, ergometrine and methylergometrine are very unstable when stored unrefrigerated, and deteriorate with higher storage temperatures and exposure to light; therefore, they need to be stored in a dark place at a temperature of 4 ºCelsius to 8 ºCelsius. Their oral forms also deteriorate within weeks or immediately after being taken from a sealed package or container or when stored in increased temperatures and high humidity. Intravenous methylergometrine administration induces both increased frequency of uterine contractions and basal tone, with a decrease of amplitude lasting at least 30 minutes and maintained for 60 to 90 minutes. The uterine effect following oral administration is detected in 20 to 30 minutes, peaks at 60 to 70 minutes and is maintained for 120 minutes, but its effect is unpredictable (<a href="./references#CD005456-bbs2-0079" title="DeGrootAN . The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1996;69(1):31‐6. ">De Groot 1996a</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). Injectable oxytocin is much more stable than ergometrine and methylergometrine (<a href="./references#CD005456-bbs2-0079" title="DeGrootAN . The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1996;69(1):31‐6. ">De Groot 1996a</a>; <a href="./references#CD005456-bbs2-0080" title="DeGrootAN , VanDongenPW , VreeTB , HeksterYA , VanRoosmalenJ . Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs1998;56(4):523‐35. ">De Groot 1998</a>; <a href="./references#CD005456-bbs2-0088" title="HogerzeilHV , WalkerGJ . Instability of (methyl)ergometrine in tropical climates: an overview. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1996;69(1):25‐9. ">Hogerzeil 1996</a>). Although the chemical instability and the side effects of ergot alkaloids are of concern, clinical trials on the use of ergot alkaloids in the third stage of labour for prevention of PPH have been conducted (<a href="./references#CD005456-bbs2-0074" title="AndersenB , AndersenLL , SorensenT . Methylergometrine during the early puerperium; a prospective randomized double blind study. Acta Obstetricia et Gynecologica Scandinavica1998;77(1):54‐7. ">Andersen 1998</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0062" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52(6):694‐7. ">Sorbe 1978</a>). Oral forms of ergot alkaloids might be useful for women in some areas where intravenous or intramuscular administration is not possible. A systematic review on the effectiveness and safety of ergot alkaloids in the third stage of labour is needed. </p> </section> <section id="CD005456-sec-0041"> <h3 class="title" id="CD005456-sec-0041">Why it is important to do this review</h3> <p>Systematic reviews on the comparison of ergot alkaloid versus oxytocin, prostaglandins, syntometrine and carbetocin are published in the<i>Cochrane Library</i> (<a href="./references#CD005456-bbs2-0090" title="McDonaldS , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201.pub2] ">McDonald 2004</a>; <a href="./references#CD005456-bbs2-0093" title="SuLL , ChongYS , SamuelM . Carbetocin for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD005457.pub4] ">Su 2012</a>; <a href="./references#CD005456-bbs2-0096" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>; <a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>). Nevertheless, there still is a gap in knowledge on the effectiveness and safety of prophylactic use of ergot alkaloids in the third stage of labour compared with no uterotonic drugs, as well as of different routes or timings of administration for the prevention of PPH. This is an update of the review which was first published in 2007 (<a href="./references#CD005456-bbs2-0106" title="LiabsuetrakulT , ChoobunT , PeeyananjarassriK , IslamQM . Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005456.pub2] ">Liabsuetrakul 2007</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005456-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005456-sec-0042"></div> <p>To determine the effectiveness and safety of prophylactic use of ergot alkaloids in the third stage of labour by any route (intravenous, intramuscular, or oral) compared with no uterotonic agents, for the prevention of postpartum haemorrhage. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005456-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005456-sec-0043"></div> <section id="CD005456-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005456-sec-0045"> <h4 class="title">Types of studies</h4> <p>All randomised trials or cluster‐randomised trials comparing prophylactic ergot alkaloids by any route (intravenous (IV), intramuscular (IM), or oral) with no uterotonic agents in the third stage of labour among women giving birth vaginally. We included trials that were presented only as abstracts if there was sufficient detail (published and unpublished) to confirm eligibility. </p> </section> <section id="CD005456-sec-0046"> <h4 class="title">Types of participants</h4> <p>Pregnant women anticipating a vaginal delivery.</p> </section> <section id="CD005456-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Any ergot alkaloid given prophylactically, by whatever route or timing of administration, compared with no uterotonic agents. Due to pharmacokinetic differences between different routes and timings of administration, we planned to evaluate separately oral versus IV or IM ergot alkaloids and administration before versus after placental delivery. </p> <p>We reviewed the following three comparisons:</p> <p> <ol id="CD005456-list-0001"> <li> <p>ergot alkaloids (any route of administration) versus no uterotonic agents;</p> </li> <li> <p>IV/IM ergot alkaloids versus no uterotonic agents;</p> </li> <li> <p>oral ergot alkaloids versus no uterotonic agents.</p> </li> </ol> </p> <p>As comparisons of ergot alkaloids with other uterotonic agents have been assessed in other reviews, such studies were not eligible for inclusion in this review. </p> </section> <section id="CD005456-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>We selected the outcome measures based on factors relating to the effectiveness and safety of ergot alkaloids in terms of clinical relevance for both maternal and neonatal outcomes. </p> <section id="CD005456-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005456-list-0002"> <li> <p>Mean blood loss (mL).</p> </li> <li> <p>Postpartum haemorrhage (PPH) (clinically estimated or measured blood loss of 500 mL or more). </p> </li> <li> <p>'Severe' PPH (clinically estimated or measured blood loss of 1000 mL or more).</p> </li> <li> <p>Maternal haemoglobin concentration at 24 to 48 hours postpartum.</p> </li> </ol> </p> </section> <section id="CD005456-sec-0050"> <h5 class="title">Secondary outcomes</h5> <section id="CD005456-sec-0051"> <h6 class="title">Maternal outcomes</h6> <p> <ol id="CD005456-list-0003"> <li> <p>Blood transfusion.</p> </li> <li> <p>Use of therapeutic uterotonics.</p> </li> <li> <p>Length of third stage of labour (minutes).</p> </li> <li> <p>Retained placenta or manual removal of the placenta, or both.</p> </li> <li> <p>Vomiting.</p> </li> <li> <p>Nausea.</p> </li> <li> <p>Elevation of blood pressure (mmHg).</p> </li> <li> <p>Pain after birth requiring analgesia (not prespecified).</p> </li> <li> <p>Headache (not prespecified).</p> </li> <li> <p>Eclamptic fit (not prespecified).</p> </li> <li> <p>Postnatal haemoglobin (Hb) less than 10 g/dL (not prespecified).</p> </li> <li> <p>Uterine subinvolution at routine follow‐up (not prespecified).</p> </li> <li> <p>Postpartum febrile morbidity (not prespecified).</p> </li> </ol> </p> </section> <section id="CD005456-sec-0052"> <h6 class="title">Neonatal outcomes</h6> <p> <ol id="CD005456-list-0004"> <li> <p>Apgar score equal to or less than six at five minutes.</p> </li> <li> <p>Jaundice.</p> </li> <li> <p>Not breastfeeding at discharge.</p> </li> <li> <p>Admission to neonatal intensive care unit.</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD005456-sec-0053"> <h3 class="title">Search methods for identification of studies</h3> <p>The following search methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD005456-sec-0054"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (19 September 2017). </p> <p>The Register is a database containing over 24,000 reports of controlled trials in the field of pregnancy and childbirth. For full search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings; and the list of journals reviewed via the current awareness service, please follow this link to the editorial information about the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth</a> in the <i>Cochrane Library</i> and select the 'Specialized Register' section from the options on the left side of the screen. </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD005456-list-0005"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD005456-bbs1-0001" title="">Included studies</a>; <a href="./references#CD005456-bbs1-0002" title="">Excluded studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) for unpublished, planned and ongoing trial reports (19 September 2017) (See <a href="./appendices#CD005456-sec-0120">Appendix 1</a> for search terms used). </p> </section> <section id="CD005456-sec-0055"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved studies. We did not apply any language or date restrictions. </p> </section> </section> <section id="CD005456-sec-0056"> <h3 class="title" id="CD005456-sec-0056">Data collection and analysis</h3> <p>For methods used in the previous version of this review, see <a href="./references#CD005456-bbs2-0106" title="LiabsuetrakulT , ChoobunT , PeeyananjarassriK , IslamQM . Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005456.pub2] ">Liabsuetrakul 2007</a>. </p> <p>For this update, the following methods were used for assessing the reports that were identified as a result of the updated search. The following methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD005456-sec-0057"> <h4 class="title">Selection of studies</h4> <p>In previous versions of the review and this updated version, the contact author (Tippawan Liabsuetrakul (TL)) assessed all potential studies identified as a result of the search strategy, using title and abstract, and searched for the full texts. Two review authors (TL and Krantarat Peeyananjarassri (KP)) independently reviewed the full texts regarding types of studies, participants, interventions and outcomes, based on the prespecified inclusion criteria and using a trial eligibility form. We resolved any disagreement through discussion or, if required, we consulted the third review author (Thanapan Choobun (TC)). </p> </section> <section id="CD005456-sec-0058"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (TL and TC)) independently assessed the validity of each included study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005456-bbs2-0086" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). There was no attempt to mask the authors' names, institutions, source of the publication or results when applying the inclusion criteria. </p> <p>We designed a form to extract data. For eligible studies, two review authors (TL and KP) independently extracted the data using the agreed form. We resolved discrepancies through discussion or, if required, we consulted the third review author. Data were entered into Review Manager software (<a href="./references#CD005456-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and checked for accuracy. </p> <p>When information regarding any of the above was unclear, we planned to contact authors of the original reports to provide further details. </p> </section> <section id="CD005456-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TL and KP) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005456-bbs2-0086" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Any disagreement was resolved by discussion or by involving a third assessor. </p> <section id="CD005456-sec-0060"> <h5 class="title">1) Random sequence generation (checking for possible selection bias)</h5> <p>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD005456-list-0006"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD005456-sec-0061"> <h5 class="title">2) Allocation concealment (checking for possible selection bias)</h5> <p>We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD005456-list-0007"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD005456-sec-0062"> <h5 class="title">3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD005456-list-0008"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD005456-sec-0063"> <h5 class="title">3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD005456-list-0009"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD005456-sec-0064"> <h5 class="title">4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re‐include missing data in the analyses which we undertook. </p> <p>We assessed methods as:</p> <p> <ul id="CD005456-list-0010"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD005456-sec-0065"> <h5 class="title">5) Selective reporting (checking for reporting bias)</h5> <p>We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as:</p> <p> <ul id="CD005456-list-0011"> <li> <p>low risk of bias (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD005456-sec-0066"> <h5 class="title">6) Other bias (checking for bias due to problems not covered by 1) to 5) above)</h5> <p>We described for each included study any important concerns we had about other possible sources of bias. </p> </section> <section id="CD005456-sec-0067"> <h5 class="title">7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Handbook</i> (<a href="./references#CD005456-bbs2-0086" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). With reference to 1) to 6) above, we planned to assess the likely magnitude and direction of the bias and whether we considered it is likely to impact on the findings. In future updates, we will explore the impact of the level of bias through undertaking sensitivity analyses; see <a href="#CD005456-sec-0081">Sensitivity analysis</a>. </p> </section> <section id="CD005456-sec-0068"> <h5 class="title">Assessment of the quality of the evidence using the GRADE approach</h5> <p>For this update, TL assessed the quality of the evidence using the GRADE approach as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a>. These assessments were checked by a second person (a Researcher from Cochrane Pregnancy and Childbirth). We assessed the quality of the body of evidence relating to the following outcomes for the main comparison. </p> <p> <ol id="CD005456-list-0012"> <li> <p>Mean blood loss (mL).</p> </li> <li> <p>PPH (clinically estimated or measured blood loss of 500 mL or more).</p> </li> <li> <p>'Severe' PPH (clinically estimated or measured blood loss of 1000 mL or more).</p> </li> <li> <p>Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL).</p> </li> <li> <p>Use of therapeutic uterotonics.</p> </li> <li> <p>Elevation of blood pressure.</p> </li> <li> <p>Pain after birth requiring analgesia.</p> </li> </ol> </p> <p>We used the <a href="http://www.guidelinedevelopment.org/" target="_blank">GRADEpro</a> Guideline Development Tool to import data from Review Manager 5 (<a href="./references#CD005456-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), in order to create ’Summary of findings’ tables. A summary of the intervention effect and a measure of quality for each of the above outcomes was produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> <section id="CD005456-sec-0069"> <h4 class="title">Measures of treatment effect</h4> <section id="CD005456-sec-0070"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals. </p> </section> <section id="CD005456-sec-0071"> <h5 class="title">Continuous data</h5> <p>We used the mean difference if outcomes were measured in the same way between trials. In future updates, if appropriate, we will use the standardised mean difference to combine trials that measure the same outcome, but use different methods. </p> </section> </section> <section id="CD005456-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <section id="CD005456-sec-0073"> <h5 class="title">Cluster‐randomised trials</h5> <p>None of the included studies were cluster‐randomised trials.</p> <p>In future updates, if identified and eligible, we will include cluster‐randomised trials in the analyses along with individually randomised trials. We will adjust their sample sizes using the methods described in the <i>Handbook,</i> using an estimate of the intracluster correlation coefficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomised trials and individually‐randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. </p> <p>We will also acknowledge heterogeneity in the randomisation unit and perform a subgroup analysis to investigate the effects of the randomisation unit. </p> </section> <section id="CD005456-sec-0074"> <h5 class="title">Cross‐over trials</h5> <p>Cross‐over trials are not eligible for inclusion.</p> </section> <section id="CD005456-sec-0075"> <h5 class="title">Other unit of analysis issues</h5> <p>Five of the included studies had more than two treatment groups (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). For these studies we included only two of the relevant groups that met the inclusion criteria in order to include data into single pair‐wise comparisons. </p> </section> </section> <section id="CD005456-sec-0076"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, levels of attrition were noted. In future updates, if more eligible studies are included, the impact of including studies with high levels of missing data in the overall assessment of treatment effect will be explored by using sensitivity analysis. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis (i.e. we attempted to include all participants randomised to each group in the analyses). The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD005456-sec-0077"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau², I² and Chi² statistics. We regarded heterogeneity as substantial if I² was greater than 30% and either Tau² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity. If we identified substantial heterogeneity (above 30%), we planned to explore it by prespecified subgroup analysis. </p> </section> <section id="CD005456-sec-0078"> <h4 class="title">Assessment of reporting biases</h4> <p>In future updates, if there are 10 or more studies in the meta‐analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it. </p> </section> <section id="CD005456-sec-0079"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager software (<a href="./references#CD005456-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect, i.e. where trials were examining the same intervention, and the trials’ populations and methods were judged sufficiently similar. </p> <p>If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we used random‐effects meta‐analysis to produce an overall summary if an average treatment effect across trials was considered clinically meaningful. The random‐effects summary was treated as the average range of possible treatment effects and we will discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will not combine trials. If we used random‐effects analyses, the results were presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I². </p> </section> <section id="CD005456-sec-0080"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses and to consider whether an overall summary was meaningful, and if so, to use random‐effects analysis to produce it. </p> <p>We planned to carry out the following subgroup analyses.</p> <p> <ol id="CD005456-list-0013"> <li> <p>Use of ergot alkaloids with or without active management of third stage of labour.</p> </li> <li> <p>Use of ergot alkaloids before or after placental delivery.</p> </li> <li> <p>Use of ergot alkaloids in different doses.</p> </li> </ol> </p> <p>There were too few studies included in any analyses with details on prespecified subgroups to make subgroup analysis possible. </p> <p>If there are enough data in future updates of this review, we will use the following outcomes in subgroup analyses. </p> <p> <ol id="CD005456-list-0014"> <li> <p>Mean blood loss (mL).</p> </li> <li> <p>PPH (clinically estimated or measured blood loss of 500 mL or more).</p> </li> <li> <p>'Severe' PPH (clinically estimated or measured blood loss of 1000 mL or more).</p> </li> <li> <p>Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL).</p> </li> </ol> </p> <p>We will assess subgroup differences by interaction tests available within Review Manager (<a href="./references#CD005456-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We will report the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value. </p> </section> <section id="CD005456-sec-0081"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses to explore the effect of risk of bias assessed by concealment of allocation, high attrition rates, or both, with studies being at high risk of bias excluded from the analyses in order to assess whether this makes any difference to the overall result. We performed a sensitivity analysis for all the outcomes which showed substantial heterogeneity by excluding trials which we classified as at high risk of bias in the main comparison. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005456-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005456-sec-0082"></div> <section id="CD005456-sec-0083"> <h3 class="title">Description of studies</h3> <section id="CD005456-sec-0084"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD005456-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD005456-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005456-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>An updated search on 19 September 2017 retrieved 42 trial reports. After screening, we excluded 30 reports and assessed 12 new reports of 11 studies. We excluded all 11 studies. For 10 of these studies, the intervention was not that of this review (<a href="./references#CD005456-bbs2-0009" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD005456-bbs2-0015" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD005456-bbs2-0020" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD005456-bbs2-0025" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. PACTR201105000292708 . Prophylactic ergometrine versus oxytocin for women in the third stage of labour: a double‐blind, randomized trial. pactr.org/ATMWeb/appmanager/atm/atmregistry?dar=true&amp;tNo=PACTR201105000292708 (first received: 2 May 2011). ">Ezeama 2014</a>; <a href="./references#CD005456-bbs2-0026" title="FawzyAEMA , SwelemM , AbdelrehimAI , TiteliS , ElghazalZS , El‐GahwagiMM , et al. Active management of third stage of labor by intravenous ergometrine and rectal versus sublingual misoprostol (a double‐center study). Alexandria Journal of Medicine2012;48(4):381‐5. ">Fawzy 2012</a>; <a href="./references#CD005456-bbs2-0033" title="GuptaM , BhosaleU . Comparative study of methylergometrine and low dose carboprost (PGF2‐x) in active management of 3rd stage labor. BJOG: an international journal of obstetrics and gynaecology2014;121(Suppl 2):139. ">Gupta 2014</a>; <a href="./references#CD005456-bbs2-0036" title="IsS , GrV , KeranahalliS . Comparison of intramuscular ergometrine and per rectal misoprostol for prophylaxis against atonic post partum haemorrhage. International Journal of Gynecology &amp; Obstetrics2012;119(Suppl 3):S797‐8. ">Is 2012</a>; <a href="./references#CD005456-bbs2-0049" title="PatilNB , PattedSS . A randomised controlled trial of oral misoprostol vs injection methylergometrine for prevention of post partum hemorrhage. International Journal of Reproduction, Contraception, Obstetrics and Gynecology2013;2(3):296‐303. ">Patil 2013</a>; <a href="./references#CD005456-bbs2-0058" title="SharmaM , KaurP , KaurK , KaurA , KaurPK , KaurMM . A comparative study of oxytocin/misoprostol/methylergometrine for active management of the third stage of labor. Journal of Obstetrics and Gynecology of India2014;64(3):175‐9. ">Sharma 2014</a>; <a href="./references#CD005456-bbs2-0059" title="ShresthaA , UralaMS , UpretiD , NiraulaS . Comparison of intramyometrial and intramuscular 15 methyl PGF2x against traditional prophylactic intramuscular methergin for the active management of third stage of labor. Nepal Journal of Obstetrics and Gynaecology2008;3(2):35‐9. ">Shrestha 2008</a>). The remaining study, identified from the clinical trials registry search, did not provide details of a contact person and so it was not possible to obtain any further information relating to the results (<a href="./references#CD005456-bbs2-0024" title="EudraCT2010‐01980‐42 . Efficacy of methylergometrine daily administration in puerperium. clinicaltrialsregister.eu/ctr‐search/trial/2010‐01980‐42/GB (first received 22 July 2010). ">EudraCT2010‐01980‐42</a>). </p> <p>We also reassessed and included two studies that were previously excluded due to not reporting outcomes of interest (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>). This updated review now includes eight randomised controlled trials. </p> </section> <section id="CD005456-sec-0085"> <h4 class="title">Included studies</h4> <p>A total of 4009 women participated in the eight included studies comparing any ergot alkaloids with placebo or no treatment (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). </p> <section id="CD005456-sec-0086"> <h5 class="title">1) Study location and settings</h5> <p>All studies were conducted in high‐income countries with low maternal mortality ratios, namely England, Hungary, Ireland, the Netherlands, the United States, France and Singapore. </p> </section> <section id="CD005456-sec-0087"> <h5 class="title">2) Participants</h5> <p>All participants included in these studies were delivered vaginally. The criteria for inclusion and exclusion were clearly defined in three studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). One study identified participants as women who had a spontaneous vaginal delivery without complications; definitions of complications were not given (<a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>). The remaining four studies included women who delivered vaginally; the exclusion criteria were not provided in the report (<a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>). Women with hypertension or cardiovascular diseases were excluded from participating in two studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). </p> </section> <section id="CD005456-sec-0088"> <h5 class="title">3) Interventions</h5> <p>The studies compared ergot alkaloids with no treatment (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>), or a placebo (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). Three studies randomised participants into three comparison groups (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>), and two studies randomised into four comparison groups (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). Ergot alkaloids used were either ergometrine/ergonovine or methylergometrine/methylergonovine/methylergobasine. There were various routes of administration: intravenous in five studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>), intramuscular in two studies (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>), and oral in one study (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). Doses of intravenous or intramuscular ergometrine or methylergometrine varied from 0.2 mg (<a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>), to 0.5 mg (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>), and no clearly defined dose (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>); and the dose of oral ergometrine was 0.4 mg (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). Most studies administered ergot alkaloids in the third stage of labour (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>); in one study administration occurred after placental delivery (<a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>). There were three studies which described the method of placental delivery: one by active management of third stage of labour (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>); two by physiological placental separation (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). The remaining studies gave no details of the method of placental delivery (<a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). There were five studies with three or more arms comparing ergot alkaloids with placebo or other uterotonic drugs (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). </p> </section> <section id="CD005456-sec-0089"> <h5 class="title">4) Outcomes</h5> <p>The largest study reported all prespecified outcome measures (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>). The following maternal outcomes not prespecified in the review are reported: postnatal haemoglobin (Hb) less than 10 g/dL (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>); headache (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>); pain after birth requiring analgesia (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>); eclamptic fit (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>); uterine subinvolution at routine follow‐up (<a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>); postpartum febrile morbidity (<a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>); prostaglandin levels (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>); and newborn birthweight and quantity of milk in 24 hours (<a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>). We did not analyse the outcome of prostaglandins, newborn birthweight and quantity of milk in this review. Blood loss was observed in six studies: clinically estimated in three (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>), measured by gravimetric method (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>), collection of blood in a container (<a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>), and non‐specified method (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>). Maternal Hb concentration was checked at 48 to 72 hours postpartum in two trials (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>). However, mean blood loss and maternal Hb concentration data could not be extracted in one study because the authors did not report the number in the result and noted only a significant difference between the comparison groups (<a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>). Two studies reported manual removal of the placenta (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>), and one study reported retained placenta for 60 minutes or more (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>). The incidence of blood transfusion was noted in three studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). The use of therapeutic uterotonics was described in three studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>). The duration of the third stage of labour was described as the mean length of the third stage (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>), and not as third stage of labour lasting more than 30 minutes, which was a prespecified outcome of this review; one of the studies did not present the standard deviations (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>), so we only analysed three studies for this outcome. The elevation of blood pressure was measured in three studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>), but the definitions varied: diastolic blood pressure greater than 95 mmHg (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>), the increase of systolic or diastolic blood pressure greater than 10 mmHg (<a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>), or the increase of systolic blood pressure 20 mmHg or more or systolic blood pressure greater than 170 mmHg (<a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). Vomiting and nausea were reported in two studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). None of the neonatal outcomes were reported in the included studies. </p> </section> <section id="CD005456-sec-0090"> <h5 class="title">5) Dates of study, funding sources and declarations of interest</h5> <p>Dates when the studies were conducted were reported as: 1 October 1987 to 31 October 1988 (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>); July 1993 to July 1994 (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>); and August 1962 to July 1963 (<a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>). In one study, it was reported that “The experiment was started in the spring of 1949”, but the completion date was not reported (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>). Study dates were not reported in four studies (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a> </p> <p>Sources of funding included: the Research and Development Trust of the Coombe Hospital in one study (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>), and a Public Health Service Grant No. GM‐08943‐02 and No. AO‐00555‐03 in another one study (<a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>). Funding sources were not reported in the remaining studies (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). </p> <p>There was no information in any of the studies on declarations of interest among primary researchers. </p> <p>Please see the table <a href="./references#CD005456-sec-0130" title="">Characteristics of included studies</a> for further details. </p> </section> </section> <section id="CD005456-sec-0091"> <h4 class="title">Excluded studies</h4> <p>The details of all excluded studies are in the table <a href="./references#CD005456-sec-0131" title="">Characteristics of excluded studies</a>. </p> <p>In the previous version of the review (<a href="./references#CD005456-bbs2-0106" title="LiabsuetrakulT , ChoobunT , PeeyananjarassriK , IslamQM . Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005456.pub2] ">Liabsuetrakul 2007</a>), we excluded 29 studies by screening using title, abstract or studies within the scope of other Cochrane Reviews. These include nine studies where the comparison was with prostaglandin (<a href="./references#CD005456-bbs2-0010" title="AmantF , SpitzB , TimmermanD , CorresmansA , VanAsscheFA . Misoprostol compared with methylergometrine for the prevention of postpartum haemorrhage: a double‐blind randomised trial. British Journal of Obstetrics and Gynaecology1999;106:1066‐70. ">Amant 1999</a>; <a href="./references#CD005456-bbs2-0013" title="BaumgartenK , SchmidtJ , HorvatA , NeumannM , CerwenkaR , GruberW , et al. Uterine motility after post‐partum application of sulprostone and other oxytocics. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1983;16(3):181‐92. ">Baumgarten 1983</a>; <a href="./references#CD005456-bbs2-0016" title="CaliskanE , MeydanliM , DilbazB , AykanB , SonmezerM , HaberalA . Is rectal misoprostol really effective in the treatment of third stage of labor? A randomized controlled trial. American Journal of Obstetrics and Gynecology2002;187(4):1038‐45. ">Caliskan 2002</a>; <a href="./references#CD005456-bbs2-0018" title="ChatterjeeA . Misoprostol and the 3rd stage. XVI FIGO World Congress of Obstetrics &amp; Gynecology (Book 4); 2000 Sept 3‐8; Washington DC, USA. 2000:29. ">Chatterjee 2000</a>; <a href="./references#CD005456-bbs2-0021" title="DiabKM , RamyAR , YehiaMA . The use of rectal misoprostol as active pharmacological management of the third stage of labor. Journal of Obstetrics &amp; Gynaecology Research1999;25(5):327‐32. ">Diab 1999</a>; <a href="./references#CD005456-bbs2-0041" title="LamH , TangOS , LeeCP , HoPC . A pilot‐randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor. Acta Obstetricia et Gynecologica Scandinavica2004;83(7):647‐50. ">Lam 2004</a>; <a href="./references#CD005456-bbs2-0052" title="PenarandaWA , ArrietaOB , YancesBR . Active management of childbirth with sublingual misoprostol: a controlled clinical trial in the Hospital de Maternidad Rafael Calvo. Revista Colombiana de Obstetricia y Ginecologia2002;53(1):87‐92. ">Penaranda 2002</a>; <a href="./references#CD005456-bbs2-0053" title="RajwaniJ , SurvanaK . Active management of third stage of labor ‐ a comparative study [abstract]. XVI FIGO World Congress of Obstetrics &amp; Gynecology (Book 3); 2000 Sept 3‐8; Washington DC, USA. 2000:54. ">Rajwani 2000</a>; <a href="./references#CD005456-bbs2-0069" title="VimalaN , MittalS , KumarS , DadhwalV , MehtaS . Sublingual misoprostol versus methylergometrine for active management of third stage of labor. International Journal of Gynecology &amp; Obstetrics2004;87(1):1‐5. ">Vimala 2004</a>); 11 studies where oxytocin was the comparator (<a href="./references#CD005456-bbs2-0012" title="BarbaroCA , SmithGO . Clinical trial of SE505 ‐ a new oxytocic mixture. Australian and New Zealand Journal of Obstetrics and Gynaecology1961;1:147‐50. ">Barbaro 1961</a>; <a href="./references#CD005456-bbs2-0014" title="BonhamDG . Intramuscular oxytocics and cord traction in third stage of labour. British Medical Journal1963;2:1620‐3. ">Bonham 1963</a>; <a href="./references#CD005456-bbs2-0022" title="DochertyPW , HooperM . Choice of an oxytocic agent for routine use at delivery. Journal of Obstetrics and Gynaecology1981;2:60. ">Docherty 1981</a>; <a href="./references#CD005456-bbs2-0028" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture (first of two trials). Australian and New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965a</a>; <a href="./references#CD005456-bbs2-0029" title="FrancisHH , MillerJM , PorteousCR . Clinical trial of an oxytocin‐ergometrine mixture (second of two trials). Australian and New Zealand Journal of Obstetrics and Gynaecology1965;5:47‐51. ">Francis 1965b</a>; <a href="./references#CD005456-bbs2-0031" title="FugoNW , DieckmannWJ . A comparison of oxytocic drugs in the management of the placental stage. American Journal of Obstetrics and Gynecology1958;76(1):141‐6. ">Fugo 1958</a>; <a href="./references#CD005456-bbs2-0035" title="HuhW , ChelmowD , MaloneFD . A randomized, double‐blinded, placebo controlled trial of oxytocin at the beginning versus the end of the third stage of labor for prevention of postpartum hemorrhage. American Journal of Obstetrics and Gynecology2000;182(1 Pt 2):S130. ">Huh 2004</a>; <a href="./references#CD005456-bbs2-0040" title="KikutaniT , ShimadaY . Effects of methylergometrine and oxytocin on thoracic epidural pressure during cesarean section. Journal of Obstetrics and Gynaecology Research2003;29(3):180‐5. ">Kikutani 2003</a>; <a href="./references#CD005456-bbs2-0061" title="SoivaK , KoistinenO . Clinical experience with simultaneous intramuscular injection of oxytocin and methylergometrine. Annales Chirurgiae et Gynaecologiae Fenniae1964;53:173‐8. ">Soiva 1964</a>; <a href="./references#CD005456-bbs2-0063" title="StearnRH . Syntometrine in the management of the third stage of labour. Journal of Obstetrics and Gynaecology of the British Commonwealth1963;70:593‐6. ">Stearn 1963</a>; <a href="./references#CD005456-bbs2-0064" title="SymesJB . A study on the effect of ergometrine on serum prolactin levels following delivery. Journal of Obstetrics and Gynaecology1984;5:36‐8. ">Symes 1984</a>); seven studies where syntometrine was the comparator (<a href="./references#CD005456-bbs2-0039" title="KhanGQ , JohnIS , ChanT , WaniS , HughesAO , StirratGM . Abu Dhabi third stage trial: oxytocin vs syntometrine in the active management of the third stage of labour. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1995;58:147‐51. ">Khan 1995</a>; <a href="./references#CD005456-bbs2-0042" title="LamontRF , MorganDJ , LogueM , GordonH . A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage. Prostaglandins &amp; Other Lipid Mediators2001;66(3):203‐10. ">Lamont 2001</a>; <a href="./references#CD005456-bbs2-0043" title="MitchellGG , ElbourneDR . The Salford third stage trial: oxytocin plus ergometrine vs oxytocin alone in the active management of the third stage of labor. Online Journal of Current Clinical Trials1993;2:Doc 83. ">Mitchell 1993</a>; <a href="./references#CD005456-bbs2-0047" title="NieminenU , JaervinenPA . A comparative study of different medical treatments of the third stage of labour. Annales Chirurgiae et Gynaecologiae Fenniae1964;53:424‐9. ">Nieminen 1963</a>; <a href="./references#CD005456-bbs2-0068" title="Vaughan WilliamsCA , JohnsonA , LedwardR . A comparison of central venous pressure changes in the third stage of labour following oxytocic drugs and diazepam. Journal of Obstetrics and Gynaecology of the British Commonwealth1974;81(8):596‐9. ">Vaughan 1974</a>; <a href="./references#CD005456-bbs2-0071" title="YardimT . Active direction of the postpartum period with Syntometrin. Der Landarzt1967;43(25):1223‐5. ">Yardim 1967</a>; <a href="./references#CD005456-bbs2-0072" title="YuenPM , ChanNST , YimSF , ChangAMZ . A randomised double blind comparison of syntometrine and syntocinon in the management of the third stage of labour. British Journal of Obstetrics and Gynaecology1995;102(5):377‐80. ">Yuen 1995</a>); one study of nipple stimulation (<a href="./references#CD005456-bbs2-0011" title="BadhwarL , SinghK , SethiN , GuptaI , AggarwalN . The value of nipple stimulation in the management of third stage of labour. Proceedings of 13th World Congress of Gynaecology and Obstetrics (FIGO); 1991 September; Singapore. 1991:16. ">Badhwar 1991</a>); and one study of syntometrine (OCM 505) (<a href="./references#CD005456-bbs2-0017" title="CarpénE , KoistinenO , VirkkunenA , LaaksoL . Clinical trial of intramuscular OCM 505 and intravenous methergin in the third stage of labour. Annales Chirurgiae et Gynaecologiae Fenniae1968;57(4):473‐5. ">Carpén 1968</a>). We then evaluated the full texts of the remaining 32 studies, and excluded 26 of these: 18 because the studied intervention was not that of this review (<a href="./references#CD005456-bbs2-0019" title='ChukudebeluWO , MarshallAT , ChalmersJA . Use of "syntometrine" in the third stage of labour. British Medical Journal1963;1(5342):1390‐1. '>Chukudebelu 1963</a>; <a href="./references#CD005456-bbs2-0027" title="ForsterFMC . A comparative study of ergometrine and 'methergin' used in the management of the third stage of labour. Medical Journal of Australia1957;2:155‐6. ">Forster 1957</a>; <a href="./references#CD005456-bbs2-0032" title="GroeberWR , BishopEH . Methergine and ergonovine in the third stage of labor. Obstetrics &amp; Gynecology1960;15:85‐8. ">Groeber 1960</a>; <a href="./references#CD005456-bbs2-0037" title="JagoAA , EzechiOC , AchingeGI , OkunlolaMA . Effect of oxytocics on the blood pressure of normotensive Nigerian parturients. Journal of Maternal‐Fetal and Neonatal Medicine2007;20(9):703‐5. ">Jago 2007</a>; <a href="./references#CD005456-bbs2-0038" title='KempJ . Clinical trial of "syntometrine" in the third stage of labour. British Medical Journal1963;1(5342):1391‐2. '>Kemp 1963</a>; <a href="./references#CD005456-bbs2-0044" title="MoirDD , AmoaAB . Ergometrine or oxytocin? Blood loss and side‐effects at spontaneous vertex delivery. British Journal of Anaesthesia1979;51:113‐7. ">Moir 1979</a>; <a href="./references#CD005456-bbs2-0045" title="MoodieJE , MoirDD . Ergometrine, oxytocin and extradural analgesia. British Journal of Anaesthesia1976;48:571‐4. ">Moodie 1976</a>; <a href="./references#CD005456-bbs2-0046" title="MooreJH . Is methylergonovine tartrate superior to ergonovine maleate. American Journal of Obstetrics and Gynecology1956;71(4):908‐11. ">Moore 1956</a>; <a href="./references#CD005456-bbs2-0048" title="OrjiE , AgwuF , LotoO , OlaleyeO . A randomized comparative study of prophylactic oxytocin versus ergometrine in the third stage of labor. International Journal of Gynecology &amp; Obstetrics2008;101(2):129‐32. ">Orji 2008</a>; <a href="./references#CD005456-bbs2-0050" title="PaullJD , RattenGJ . Ergometrine and third stage blood loss. Medical Journal of Australia1977;1:178‐9. ">Paull 1977</a>; <a href="./references#CD005456-bbs2-0051" title="PeiJL , ZhaoDF . Study of the effects of using uterine stimulants on milk secretion during delivery. Zhonghua Hu Li Za Zhi [Chinese Journal of Nursing]1996;31(7):384‐5. ">Pei 1996</a>; <a href="./references#CD005456-bbs2-0054" title="RameshS , BhatnagarB , KarnaS , Ranjana . Role of intramyometrial prostaglandin E2 in management of third stage of labour. Indian Journal of Medical Research1983;77:642‐7. ">Ramesh 1983</a>; <a href="./references#CD005456-bbs2-0055" title="ReddyR , ShenoyJV . Active management of third stage of labour. A comparative study in high risk patients for atonic postpartum haemorrhage. Journal of Obstetrics and Gynecology of India2001;51(2):44‐7. ">Reddy 2001</a>; <a href="./references#CD005456-bbs2-0056" title="RooneyI , HughesP , CalderAA . Is routine administration of syntometrine still justified in the management of the third stage of labour?. Health Bulletin1985;43(3):99‐101. ">Rooney 1985</a>; <a href="./references#CD005456-bbs2-0057" title="SaitoK , HarukiA , IshikawaH , TakahashiT , NagaseH , KoyamaM , et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research2007;33(3):254‐8. ">Saito 2007</a>; <a href="./references#CD005456-bbs2-0060" title="SinghG , RadhakrishnanG , GuleriaK . Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology &amp; Obstetrics2009;107(2):130‐4. ">Singh 2009</a>; <a href="./references#CD005456-bbs2-0066" title="ThilaganathanB , CutnerA , LatimerJ , BeardR . Management of the third stage of labour in women at low risk of postpartum haemorrhage. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1993;48(1):19‐22. ">Thilaganathan 1993</a>; <a href="./references#CD005456-bbs2-0067" title="ThorntonS , DavisonJM , BaylisPH . Plasma oxytocin during third stage of labour: comparison of natural and active management. BMJ1988;297(6642):167‐9. ThorntonS , DavisonJM , BaylisPH . Plasma oxytocin in the third stage of human labour with and without syntometrine [abstract]. Clinical Science1987;73 Suppl(17):2P. ">Thornton 1988</a>); three because the studies were not randomised controlled trials (<a href="./references#CD005456-bbs2-0030" title="FriedmanEA . Comparative clinical evaluation of postpartum oxytocics. American Journal of Obstetrics and Gynecology1957;73(6):1306‐13. ">Friedman 1957</a>; <a href="./references#CD005456-bbs2-0034" title="HackerNF , BiggsJSG . Blood pressure changes when uterine stimulants are used after normal delivery. British Journal of Obstetrics and Gynaecology1979;86(8):633‐6. ">Hacker 1979</a>; <a href="./references#CD005456-bbs2-0062" title="SorbeB . Active pharmacologic management of the third stage of labor. A comparison of oxytocin and ergometrine. Obstetrics &amp; Gynecology1978;52(6):694‐7. ">Sorbe 1978</a>); one because it did not include women having a vaginal delivery (<a href="./references#CD005456-bbs2-0023" title="DweckMF , LynchCM , SpellacyWN . Use of methergine for the prevention of postoperative endometritis in non‐elective cesarean section patients. Infectious Diseases in Obstetrics &amp; Gynecology2000;8(3‐4):151‐4. ">Dweck 2000</a>); and four because there were no outcomes of interest (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0065" title="TerryMF . A management of the third stage to reduce feto‐maternal transfusion. Journal of Obstetrics and Gynaecology of the British Commonwealth1970;77(2):129‐32. ">Terry 1970</a>; <a href="./references#CD005456-bbs2-0070" title="WeissG , KleinS , ShenkmanL , KataokaK , HollanderCS . Effect of methylergonovine on puerperal prolactin secretion. Obstetrics &amp; Gynecology1975;46(2):209‐10. ">Weiss 1975</a>). However, in this current update, we reassessed four studies to make sure the reasons for exclusion were still valid and could not introduce outcome reporting bias (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0065" title="TerryMF . A management of the third stage to reduce feto‐maternal transfusion. Journal of Obstetrics and Gynaecology of the British Commonwealth1970;77(2):129‐32. ">Terry 1970</a>; <a href="./references#CD005456-bbs2-0070" title="WeissG , KleinS , ShenkmanL , KataokaK , HollanderCS . Effect of methylergonovine on puerperal prolactin secretion. Obstetrics &amp; Gynecology1975;46(2):209‐10. ">Weiss 1975</a>). Two studies were still excluded (<a href="./references#CD005456-bbs2-0065" title="TerryMF . A management of the third stage to reduce feto‐maternal transfusion. Journal of Obstetrics and Gynaecology of the British Commonwealth1970;77(2):129‐32. ">Terry 1970</a>; <a href="./references#CD005456-bbs2-0070" title="WeissG , KleinS , ShenkmanL , KataokaK , HollanderCS . Effect of methylergonovine on puerperal prolactin secretion. Obstetrics &amp; Gynecology1975;46(2):209‐10. ">Weiss 1975</a>): we excluded one because the comparison was with syntometrine (<a href="./references#CD005456-bbs2-0065" title="TerryMF . A management of the third stage to reduce feto‐maternal transfusion. Journal of Obstetrics and Gynaecology of the British Commonwealth1970;77(2):129‐32. ">Terry 1970</a>), and one because it did not measure any outcomes from this review (<a href="./references#CD005456-bbs2-0070" title="WeissG , KleinS , ShenkmanL , KataokaK , HollanderCS . Effect of methylergonovine on puerperal prolactin secretion. Obstetrics &amp; Gynecology1975;46(2):209‐10. ">Weiss 1975</a>). We included the remaining two studies (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>), but one did not contribute any data to the review (<a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>). </p> <p>We excluded the 11 studies from the 2017 search. The intervention used in 10 studies was not that of this review (<a href="./references#CD005456-bbs2-0009" title="AdhikariS , RanaA , BistaKD . Active management of third stage of labour: comparison between prophylactic intramuscular methylergometrine and intramuscular oxytocin. Nepal Journal of Obstetrics and Gynaecology2007;2(2):24‐8. ">Adhikari 2007</a>; <a href="./references#CD005456-bbs2-0015" title="BoopathiA , NayakSR , RaoA , RaoB . Oxytocin versus methylergometrine in the active management of third stage of labour. Open Journal of Obstetrics and Gynecology2014;4:666‐71. ">Boopathi 2014</a>; <a href="./references#CD005456-bbs2-0020" title="DhananjayaBS , CharishmaS . Comparative study of efficacy and safety of intramuscular oxytocin with intramuscular methylergometrine in the active management of third stage of labour. Research Journal of Pharmaceutical, Biological and Chemical Sciences2014;5(3):734‐9. ">Dhananjaya 2014</a>; <a href="./references#CD005456-bbs2-0025" title="EzeamaCO , ElejeGU , EzeamaNN , IgwegbeAO , IkechebeluJI , UgboajaJO , et al. A comparison of prophylactic intramuscular ergometrine and oxytocin for women in the third stage of labor. International Journal of Gynecology and Obstetrics2014;124(1):67‐71. PACTR201105000292708 . Prophylactic ergometrine versus oxytocin for women in the third stage of labour: a double‐blind, randomized trial. pactr.org/ATMWeb/appmanager/atm/atmregistry?dar=true&amp;tNo=PACTR201105000292708 (first received: 2 May 2011). ">Ezeama 2014</a>; <a href="./references#CD005456-bbs2-0026" title="FawzyAEMA , SwelemM , AbdelrehimAI , TiteliS , ElghazalZS , El‐GahwagiMM , et al. Active management of third stage of labor by intravenous ergometrine and rectal versus sublingual misoprostol (a double‐center study). Alexandria Journal of Medicine2012;48(4):381‐5. ">Fawzy 2012</a>; <a href="./references#CD005456-bbs2-0033" title="GuptaM , BhosaleU . Comparative study of methylergometrine and low dose carboprost (PGF2‐x) in active management of 3rd stage labor. BJOG: an international journal of obstetrics and gynaecology2014;121(Suppl 2):139. ">Gupta 2014</a>; <a href="./references#CD005456-bbs2-0036" title="IsS , GrV , KeranahalliS . Comparison of intramuscular ergometrine and per rectal misoprostol for prophylaxis against atonic post partum haemorrhage. International Journal of Gynecology &amp; Obstetrics2012;119(Suppl 3):S797‐8. ">Is 2012</a>; <a href="./references#CD005456-bbs2-0049" title="PatilNB , PattedSS . A randomised controlled trial of oral misoprostol vs injection methylergometrine for prevention of post partum hemorrhage. International Journal of Reproduction, Contraception, Obstetrics and Gynecology2013;2(3):296‐303. ">Patil 2013</a>; <a href="./references#CD005456-bbs2-0058" title="SharmaM , KaurP , KaurK , KaurA , KaurPK , KaurMM . A comparative study of oxytocin/misoprostol/methylergometrine for active management of the third stage of labor. Journal of Obstetrics and Gynecology of India2014;64(3):175‐9. ">Sharma 2014</a>; <a href="./references#CD005456-bbs2-0059" title="ShresthaA , UralaMS , UpretiD , NiraulaS . Comparison of intramyometrial and intramuscular 15 methyl PGF2x against traditional prophylactic intramuscular methergin for the active management of third stage of labor. Nepal Journal of Obstetrics and Gynaecology2008;3(2):35‐9. ">Shrestha 2008</a>), and one study identified from the clinical trials registry search did not provide details of a contact person and so it was not possible to obtain any further information relating to the results (<a href="./references#CD005456-bbs2-0024" title="EudraCT2010‐01980‐42 . Efficacy of methylergometrine daily administration in puerperium. clinicaltrialsregister.eu/ctr‐search/trial/2010‐01980‐42/GB (first received 22 July 2010). ">EudraCT2010‐01980‐42</a>). </p> </section> </section> <section id="CD005456-sec-0092"> <h3 class="title">Risk of bias in included studies</h3> <p>According to the 'Risk of bias' tool, three studies had a low risk of bias (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>), and five studies showed a high risk of bias (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>) (<a href="#CD005456-fig-0002">Figure 2</a>; <a href="#CD005456-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD005456-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005456-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005456-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005456-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005456-sec-0093"> <h4 class="title">Allocation</h4> <p>We considered two studies to have adequate sequence generation and allocation concealment (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). Sequence generation and allocation concealment were inadequate in one study due to the use of alternation by weekends when teams of obstetricians and midwives changed (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>). We were unable to make a judgement about whether sequence generation and allocation concealment was adequate or inadequate in five studies due to there being no details of the methods used (<a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). We did not request additional information regarding allocation concealment from the trial authors of these studies because they were published before 1980. </p> </section> <section id="CD005456-sec-0094"> <h4 class="title">Blinding</h4> <p>We assessed that the method of blinding (participants and caregiver) was of low risk of bias in two studies that compared ergometrine/methylergometrine with placebo (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>). One study mentioned that normal saline was used as the control; however, the appearance of methergine or ergonovine was not described (i.e. whether it was identical with control) thus we judged its blinding as unclear (<a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). Due to the comparison being no treatment or different route of drug administration in the remaining studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>), we considered that it was not possible to blind and so deemed these studies to be at high risk of performance bias. </p> <p>In two studies we judged that it was possible for blinding of outcome assessment to be performed (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>); we judged that it was unlikely that blinding of outcome assessment was possible in five studies (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>); and we judged that it was not clear whether it was possible to perform blinding of outcome assessment in one study (<a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). </p> </section> <section id="CD005456-sec-0095"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed that all participants who entered the study were accounted for in the outcome measures and analyses in five trials (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>). In <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>, not all participants who entered the study were accounted for in the outcome measures and analyses, but the loss of participants at follow‐up was less than 10%. In two studies, a number of participants in the outcomes identified were not reported (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>), and so we deemed these studies to have high risk of bias for this domain. </p> </section> <section id="CD005456-sec-0096"> <h4 class="title">Selective reporting</h4> <p>We assessed that in seven included trials published all expected prespecified outcomes in the reports. One study reported one additional outcome in the results which was not defined in the methods, thus we rated as high risk of reporting bias (<a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>). </p> </section> <section id="CD005456-sec-0097"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify other important potential source of bias.</p> </section> </section> <section id="CD005456-sec-0098"> <h3 class="title" id="CD005456-sec-0098">Effects of interventions</h3> <p>See: <a href="./full#CD005456-tbl-0001"><b>Summary of findings for the main comparison</b> Ergot alkaloids (any route of administration) versus no uterotonic agents in the third stage of labour</a>; <a href="./full#CD005456-tbl-0002"><b>Summary of findings 2</b> Intravenous/intramuscular ergot alkaloids versus no uterotonic agents in the third stage of labour</a>; <a href="./full#CD005456-tbl-0003"><b>Summary of findings 3</b> Oral ergot alkaloids versus no uterotonic agents in the third stage of labour</a> </p> <p>We included eight studies with a total of 4009 women: 2031 women in the ergot alkaloids group and 1978 in the placebo or no treatment group. We analysed data from seven studies comparing ergot alkaloids with no uterotonic agents, with a total of 2001 women in the ergot alkaloids group and 1950 women in the placebo or no treatment group. Effects of interventions are presented in three comparisons: any route of administration, intravenous/intramuscular administration, or oral regimens, versus no uterotonic agents (seven, six and one included studies, respectively). We performed a sensitivity analysis for the outcomes which showed substantial heterogeneity by excluding trials which we classified as having high risk of bias. Where significant heterogeneity was observed, we analysed results using a random‐effects model. </p> <section id="CD005456-sec-0099"> <h4 class="title">1) Ergot alkaloids (any route of administration) versus no uterotonic agents</h4> <section id="CD005456-sec-0100"> <h5 class="title">Primary outcomes</h5> <p>For four primary outcomes, five included studies compared any route of ergot alkaloids with no treatment, of which four studies used the intravenous/intramuscular route of administration (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>), and one study used the oral route (<a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). The use of ergot alkaloids decreased mean blood loss (mean difference (MD) ‐80.52 mL, 95% confidence interval (CI) ‐96.39 to ‐64.65 mL; 3 studies, 2718 women; moderate‐quality evidence; <a href="./references#CD005456-fig-0004" title="">Analysis 1.1</a>). Postpartum haemorrhage (PPH), blood loss of at least 500 mL, was also reduced with ergot alkaloids (average risk ratio (RR) 0.52, 95% CI 0.28 to 0.94; random‐effects, Tau² = 0.32, I² = 83%; 123/1851 versus 220/1857 women; 5 studies, 3708 women, low‐quality evidence; <a href="./references#CD005456-fig-0005" title="">Analysis 1.2</a>). There were no clear differences in blood loss of at least 1000 mL between the ergot alkaloids and no treatment groups (average RR 0.32, 95% CI 0.04 to 2.59; random‐effects, Tau² = 1.74, I² = 74%; 13/851 versus 27/867 women; 1 study, 1429 women; very low‐quality evidence; <a href="./references#CD005456-fig-0006" title="">Analysis 1.3</a>). There was an increase in mean maternal haemoglobin concentration at 48 to 72 hours of postpartum in the ergot alkaloids group, but data were only reported in one study (MD 0.50 g/dL, 95% CI 0.38 to 0.62; 1 study, 1429 women; <a href="./references#CD005456-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD005456-sec-0101"> <h5 class="title">Secondary outcomes</h5> <p>No difference was demonstrated in the incidence of blood transfusion when ergot alkaloid was compared with no uterotonic agents (RR 0.33, 95% CI 0.08 to 1.40; 2/951 versus 6/917 women; 3 studies, 1868 women; <a href="./references#CD005456-fig-0008" title="">Analysis 1.5</a>), but use of ergot alkaloid did reduce the use of therapeutic uterotonics (average RR 0.37, 95% CI 0.15 to 0.90; random‐effects, Tau² = 0.56, I² = 89%; 60/1356 versus 177/1342 women; 3 studies, 2698 women; low‐quality evidence, <a href="./references#CD005456-fig-0009" title="">Analysis 1.6</a>). Compared with no treatment, ergot alkaloids reduced the mean length of the third stage of labour by nearly two minutes (MD ‐1.70 minutes, 95% CI ‐3.33 to ‐0.06; random‐effects, Tau² = 3.68, I² = 94%; 3 studies, 2522 women, <a href="./references#CD005456-fig-0010" title="">Analysis 1.7</a>), but there were no differences between groups in the risk of retained placenta or manual removal of the placenta (average RR 3.86, 95% CI 0.36 to 41.78; random‐effects, Tau² = 3.43, I² = 81%; 38/1341 versus 20/1377 women; 3 studies, 2718 women; <a href="./references#CD005456-fig-0011" title="">Analysis 1.8</a>). </p> <p>For the remaining maternal secondary outcomes, only the intravenous or intramuscular route of administration was used (three studies: <a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>); therefore, the results were similar to the findings of comparisons of intramuscular or intramuscular ergot alkaloids compared with no uterotonic agents, reported below in comparison two. We could not find the studies reporting neonatal secondary outcomes. </p> <p>The number of included studies was too few to conduct subgroup analyses based on the use of ergot alkaloids with or without active management of third stage of labour, before or after placental delivery, and in different doses. </p> <p>None of the studies reported on any of our prespecified neonatal outcomes: Apgar score equal to or less than six at five minutes; jaundice; not breastfeeding at discharge; and admission to neonatal intensive care. </p> <section id="CD005456-sec-0102"> <h6 class="title">Sensitivity analyses</h6> <p>There were three studies at high risk of bias for either allocation concealment or attrition bias (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>). We excluded these studies for the following analyses: mean blood loss (mL) (<a href="./references#CD005456-fig-0004" title="">Analysis 1.1</a>); estimated or measured blood loss of at least 500 mL (<a href="./references#CD005456-fig-0005" title="">Analysis 1.2</a>); length of third stage of labour (minutes) (<a href="./references#CD005456-fig-0010" title="">Analysis 1.7</a>); retained placenta or manual removal of placenta, or both (<a href="./references#CD005456-fig-0011" title="">Analysis 1.8</a>). This made little difference to the overall results for mean blood loss (mL) (<a href="./references#CD005456-fig-0044" title="">Analysis 4.1</a>). After excluding two trials (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>), for estimated or measured blood loss of at least 500 mL the confidence intervals increased slightly to cross the line of no effect and heterogeneity increased (average RR 0.44, 95% CI 0.16 to 1.24; 3 studies, 2698 women; I<sup>2</sup> = 92%; <a href="./references#CD005456-fig-0045" title="">Analysis 4.2</a>). For length of third stage of labour (minutes), excluding one study, <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>, again resulted in the confidence interval increasing slightly to cross the line of no effect, but heterogeneity decreased from 66% to 42% (MD ‐1.07 minutes, 95% CI ‐2.32 to 0.19; 2 studies, 1522 women; I<sup>2</sup> = 42%; <a href="./references#CD005456-fig-0046" title="">Analysis 4.3</a>). For the outcome retained placenta or manual removal of placenta, removing one study, <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>, from the analysis changed the direction of effect from no difference to a reduction in retained placenta or manual removal of placenta in favour of the control group and heterogeneity completely disappeared (RR 12.79, 95% CI 2.40 to 68.19; 2 studies, 1718 women; I<sup>2</sup> = 0%; <a href="./references#CD005456-fig-0047" title="">Analysis 4.4</a>). </p> </section> </section> </section> <section id="CD005456-sec-0103"> <h4 class="title">2) Intravenous or intramuscular ergot alkaloids compared with no uterotonic agents</h4> <section id="CD005456-sec-0104"> <h5 class="title">Primary outcomes</h5> <p>Four included studies compared the intravenous/intramuscular route of administration of ergot alkaloids with no treatment (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>). Two studies comparing intravenous/intramuscular ergot alkaloids with no treatment, found that the use of ergot alkaloids decreased mean blood loss (mean difference (MD) ‐81.75 mL, 95% confidence interval (CI) ‐97.88 to ‐65.61 mL; 2 studies, 2429 women; moderate‐quality evidence; <a href="./references#CD005456-fig-0021" title="">Analysis 2.1</a>). When blood loss of at least 500 mL (moderate PPH) was considered, there was significant heterogeneity, thus we analysed this outcome using a random‐effects model and ergot alkaloids were associated with a lower moderate PPH rate (average RR 0.41, 95% CI 0.22 to 0.75; random‐effects, Tau² = 0.22, I² = 67%; 69/1705 versus 165/1714 women; 4 studies, 3419 women; low‐quality evidence; <a href="./references#CD005456-fig-0022" title="">Analysis 2.2</a>). One study comparing ergot alkaloids with no treatment, reported a reduction in blood loss of at least 1000 mL (RR 0.09, 95% CI 0.01 to 0.72; 1 study, 1429 women; low‐quality evidence; <a href="./references#CD005456-fig-0023" title="">Analysis 2.3</a>) and increased mean maternal haemoglobin concentration at 48 to 72 hours postpartum (MD 0.50 g/dL, 95% CI 0.38 to 0.62; 1 study, 1429 women; moderate‐quality evidence; <a href="./references#CD005456-fig-0024" title="">Analysis 2.4</a>) with ergot alkaloids. </p> </section> <section id="CD005456-sec-0105"> <h5 class="title">Secondary outcomes</h5> <p>No difference was demonstrated in the incidence of blood transfusion when ergot alkaloid was compared with no uterotonic agents (RR 0.34, 95% CI 0.05 to 2.16; 1/805 versus 3/774 women; 2 studies, 1579 women; <a href="./references#CD005456-fig-0025" title="">Analysis 2.5</a>), but use of an ergot alkaloid did reduce the use of therapeutic uterotonics (average RR 0.25, 95% CI 0.10 to 0.66; random‐effects, Tau² = 0.41, I² = 86%; 39/1210 versus 151/1199 women; 2 studies, 2409 women; low‐quality evidence; <a href="./references#CD005456-fig-0026" title="">Analysis 2.6)</a>. Mean length of third stage of labour was significantly less in the ergot alkaloid group (MD ‐1.70 minutes, 95% CI ‐3.33 to ‐0.06; Tau² = 1.36, I² = 66%; 3 studies, 2522 women; <a href="./references#CD005456-fig-0027" title="">Analysis 2.7</a>) using random‐effects analysis. </p> <p>The risk of retained placenta or manual removal of the placenta, or both, was not demonstrated (average RR 3.75, 95% CI 0.14 to 99.71; random‐effects, Tau² = 5.06, I² = 90%; 36/1195 versus 20/1234 women; 2 studies, 2429 women; <a href="./references#CD005456-fig-0028" title="">Analysis 2.8</a>). It should be noted that the outcomes of these two studies had opposite directions of effect. In one study (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>), the risk of manual removal of placenta was increased in the ergot alkaloid group (RR 19.51, 95% CI 2.62 to 145.36), but in the other study (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>), the risk of retained placenta at 60 minutes or more was not increased. </p> <p>In two studies, vomiting and nausea were increased with ergot alkaloids (vomiting: average RR 6.82, 95% CI 0.37 to 126.26; random‐effects, Tau² = 2.10, I² = 47%; 13/805 versus 0/774 women; 2 studies, 1579 women; <a href="./references#CD005456-fig-0029" title="">Analysis 2.9</a>; nausea: average RR 8.63, 95% CI 0.26 to 284.55; random‐effects, Tau² = 4.04, I² = 63%; 21/805 versus 0/774 women; 2 studies, 1579 women; <a href="./references#CD005456-fig-0030" title="">Analysis 2.10</a>). The following maternal adverse effects were increased with intravenous or intramuscular ergot alkaloids compared with no treatment: elevation of blood pressure (average RR 2.60, 95% CI 1.03 to 6.57; random‐effects; Tau² = 0.55, I² = 84%; 299/1310 versus 166/1249 women; 3 studies, 2559 women; low‐quality evidence; <a href="./references#CD005456-fig-0031" title="">Analysis 2.11</a>); and pain after birth requiring analgesia (RR 2.53, 95% CI 1.34 to 4.78; 1 study, 1429 women; moderate‐quality evidence; <a href="./references#CD005456-fig-0032" title="">Analysis 2.12</a>). Significant heterogeneity for the outcome elevation of blood pressure might be because different definitions of elevated blood pressure were used. </p> <p>None of the studies reported on any of our prespecified neonatal outcomes: Apgar score equal to or less than six at five minutes; jaundice; not breastfeeding at discharge; and admission to neonatal intensive care. </p> </section> <section id="CD005456-sec-0106"> <h5 class="title">Outcomes not prespecified</h5> <p>There was no evidence of a difference in the incidence of headache (<a href="./references#CD005456-fig-0033" title="">Analysis 2.13</a>) and eclamptic fits (<a href="./references#CD005456-fig-0034" title="">Analysis 2.14</a>). One study reported no difference of uterine subinvolution at routine follow‐up (<a href="./references#CD005456-fig-0035" title="">Analysis 2.15</a>), and postpartum febrile morbidity (<a href="./references#CD005456-fig-0036" title="">Analysis 2.16</a>). One study reported a significant reduction of postnatal haemoglobin less than 10 g/dL (RR 0.30, 95% CI 0.14 to 0.67; 1 study, 1429 women; <a href="./references#CD005456-fig-0037" title="">Analysis 2.17</a>). </p> </section> </section> <section id="CD005456-sec-0107"> <h4 class="title">3) Oral ergot alkaloids compared with no uterotonic agents</h4> <p>One study, <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>, compared oral ergometrine with placebo and showed no significant benefit of ergometrine over placebo in terms of mean blood loss (<a href="./references#CD005456-fig-0038" title="">Analysis 3.1</a>); blood loss of at least 500 mL (<a href="./references#CD005456-fig-0039" title="">Analysis 3.2</a>) and 1000 mL (<a href="./references#CD005456-fig-0040" title="">Analysis 3.3</a>); need for blood transfusion (<a href="./references#CD005456-fig-0041" title="">Analysis 3.4</a>); use of further oxytocics (<a href="./references#CD005456-fig-0042" title="">Analysis 3.5</a>); and manual removal of the placenta (<a href="./references#CD005456-fig-0043" title="">Analysis 3.6</a>). Data presented for length of third stage of labour could not be extracted. No maternal adverse effects were reported. None of our prespecified neonatal outcomes were reported: Apgar score equal to or less than six at five minutes; jaundice; not breastfeeding at discharge; and admission to neonatal intensive care. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005456-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005456-sec-0108"></div> <section id="CD005456-sec-0109"> <h3 class="title" id="CD005456-sec-0109">Summary of main results</h3> <p>There was moderate‐quality evidence that the use of ergot alkaloids probably reduces mean blood loss, probably slightly reduces moderate postpartum haemorrhage (PPH) (low‐quality evidence) and the use of therapeutic uterotonics (low‐quality evidence), and probably increases postnatal haemoglobin (Hb) level. Nevertheless, there was very low‐quality evidence that the intervention probably makes little difference to severe PPH. Furthermore, there was moderate‐quality evidence that the use of ergot alkaloids probably leads to an increase in the frequency of women requiring analgesia after birth due to pain. There was also low‐quality evidence to suggest that ergot alkaloids may slightly increase elevation of blood pressure. The use of intravenous/intramuscular ergot alkaloids may make little or no difference in terms of other adverse effects (vomiting, nausea, headache or eclamptic fit) and results were inconsistent on the risks of retained or manual removal of placenta. </p> </section> <section id="CD005456-sec-0110"> <h3 class="title" id="CD005456-sec-0110">Overall completeness and applicability of evidence</h3> <p>Intravenous/intramuscular ergot alkaloids decreased mean blood loss and reduced the incidence of postpartum blood loss of at least 500 mL, which is in accordance with the results of a Cochrane Review assessing the effectiveness of active versus expectant management in the third stage of labour (<a href="./references#CD005456-bbs2-0075" title="BegleyCM , GyteGML , MurphyDJ , DevaneD , McDonaldSJ , McGuireW . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD007412.pub4] ">Begley 2015</a>). Postpartum blood loss of 1000 mL or more and postnatal Hb concentration less than 10 g/dL were decreased, and there was an increase in mean postnatal Hb in the intravenous ergot alkaloids group, but data were from one study only (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>). These effects can result from strong uterine contractions after giving ergot alkaloids (<a href="./references#CD005456-bbs2-0078" title="DeGrootAN . Prevention of postpartum haemorrhage. Bailliere’s Clinical Obstetrics and Gynaecology1995;9(3):619‐31. ">De Groot 1995</a>; <a href="./references#CD005456-bbs2-0079" title="DeGrootAN . The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1996;69(1):31‐6. ">De Groot 1996a</a>; <a href="./references#CD005456-bbs2-0080" title="DeGrootAN , VanDongenPW , VreeTB , HeksterYA , VanRoosmalenJ . Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs1998;56(4):523‐35. ">De Groot 1998</a>), leading to a reduction in the need for therapeutic uterotonics, but no change in the incidence of blood transfusion. The reduction in the need for therapeutic uterotonics was also found in the Cochrane Reviews of oxytocin versus no uterotonic agents (<a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>) and active versus expectant management in the third stage of labour (<a href="./references#CD005456-bbs2-0075" title="BegleyCM , GyteGML , MurphyDJ , DevaneD , McDonaldSJ , McGuireW . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD007412.pub4] ">Begley 2015</a>). Mean length of the third stage of labour in the ergot alkaloid group in this review was minimally decreased (two minutes); however, previous Cochrane Reviews on prophylactic use of other uterotonics in the third stage of labour compared with no uterotonic agents have not shown this benefit (<a href="./references#CD005456-bbs2-0096" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>; <a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>). Two‐minute reduction in the third stage of labour seems unlikely to be clinically significant; however, it is a very critical period in case of bleeding. </p> <p>No difference was demonstrated for the risk of retained placenta or manual removal of the placenta, or both; heterogeneity was high (81%) and confidence intervals wide (three trials: <a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>). This finding was in accordance with the results of the Cochrane Reviews of uterotonic versus no uterotonic agents (<a href="./references#CD005456-bbs2-0096" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>; <a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>) and active versus expectant management in the third stage of labour (<a href="./references#CD005456-bbs2-0075" title="BegleyCM , GyteGML , MurphyDJ , DevaneD , McDonaldSJ , McGuireW . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD007412.pub4] ">Begley 2015</a>). Likewise, this lack of a difference was also found in a Cochrane review comparing a combination of ergot alkaloid and oxytocin versus oxytocin (<a href="./references#CD005456-bbs2-0090" title="McDonaldS , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201.pub2] ">McDonald 2004</a>). </p> <p>Significant adverse events for elevation of blood pressure and pain after birth requiring analgesia result from the effects of ergot alkaloids caused by persistent uterine contraction and vasoconstriction (<a href="./references#CD005456-bbs2-0080" title="DeGrootAN , VanDongenPW , VreeTB , HeksterYA , VanRoosmalenJ . Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs1998;56(4):523‐35. ">De Groot 1998</a>; <a href="./references#CD005456-bbs2-0081" title="DenHertogCE , DeGrootAN , VanDongenPW . History and use of oxytocics. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2001;94(1):8‐12. ">Den Hertog 2001</a>; <a href="./references#CD005456-bbs2-0097" title="VanDongenPW , DeGrootAN . History of ergot alkaloids from ergotism to ergometrine. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1995;60(2):109‐16. ">Van Dongen 1995</a>), in accordance with the Cochrane Reviews (<a href="./references#CD005456-bbs2-0075" title="BegleyCM , GyteGML , MurphyDJ , DevaneD , McDonaldSJ , McGuireW . Active versus expectant management for women in the third stage of labour. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD007412.pub4] ">Begley 2015</a>;<a href="./references#CD005456-bbs2-0090" title="McDonaldS , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201.pub2] ">McDonald 2004</a>). Data from case reports reported severe adverse effects (cerebral ischaemia, vasospasm and hypertensive encephalopathy) (<a href="./references#CD005456-bbs2-0082" title="DuaJA . Postpartum eclampsia associated with ergometrine maleate administration. British Journal of Obstetrics and Gynaecology1994;101(1):72‐3. ">Dua 1994</a>; <a href="./references#CD005456-bbs2-0095" title="TaylorGJ , CohenB . Ergonovine‐induced coronary artery spasm and myocardial infarction after normal delivery. Obstetrics &amp; Gynecology1985;66(6):821‐2. ">Taylor 1985</a>), indicating that the drug should be used with caution. There was only one study, <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>, comparing oral ergometrine versus placebo, which showed no significant risk or benefit of ergometrine. This may be explained by there being only a small number of women in the study, and therefore insufficient power to detect any difference. Easy deterioration of oral ergot alkaloids immediately after being taken from a sealed package or container, and from being exposed to increased temperature and high humidity (<a href="./references#CD005456-bbs2-0080" title="DeGrootAN , VanDongenPW , VreeTB , HeksterYA , VanRoosmalenJ . Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs1998;56(4):523‐35. ">De Groot 1998</a>), or longer latency time and less effect on uterine motility when compared with the intravenous route, can lead to unpredictable bioavailability (<a href="./references#CD005456-bbs2-0079" title="DeGrootAN . The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology1996;69(1):31‐6. ">De Groot 1996a</a>). </p> <p>According to the magnitude of ergot alkaloid effect, 19 pregnant women would need to be given ergot alkaloids to prevent one additional pregnant woman from experiencing moderate PPH (number needed to treat for an additional beneficial outcome (NNTB) 19, 95% confidence interval (CI) 14 to 30), with simultaneous harm of pain after birth (number needed to treat for an additional harmful outcome (NNTH) 36, 95% CI 22 to 108) and elevation of blood pressure (NNTH 10, 95% CI 8 to 15). Thus, with the possible elevation in blood pressure, ergot alkaloids should be used with caution in those women with high blood pressure. </p> </section> <section id="CD005456-sec-0111"> <h3 class="title" id="CD005456-sec-0111">Quality of the evidence</h3> <p>We included eight randomised controlled trials in this review. According to the 'Risk of bias' tool, three studies had a low risk of bias (<a href="./references#CD005456-bbs2-0001" title="BegleyCM . Comparative studies in the third stage of labour [MSc thesis]. Dublin: Trinity College, University of Dublin, 1990. BegleyCM . A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery1990;6:3‐17. BegleyCM . The effect of ergometrine on breast feeding. Midwifery1990;6:60‐72. ">Begley 1990</a>; <a href="./references#CD005456-bbs2-0003" title="DeGrootANJA , VanRoosmalenJ , VanDongenPWJ , BormGF . A placebo‐controlled trial of oral ergometrine to reduce postpartum hemorrhage. Acta Obstetricia et Gynecologica Scandinavica1996;75(5):464‐8. ">De Groot 1996b</a>; <a href="./references#CD005456-bbs2-0004" title="HowardWF , McFaddenPR , KeettelWC . Oxytocic drugs in fourth stage of labor. JAMA1964;189:411‐3. ">Howard 1964</a>), and five studies showed a high risk of bias (<a href="./references#CD005456-bbs2-0002" title="DaleyD . The use of intramuscular ergometrine at the end of the second stage of normal labour. Journal of Obstetrics and Gynaecology of the British Empire1951;58(3):388‐97. ">Daley 1951</a>; <a href="./references#CD005456-bbs2-0005" title="IlancheranA , RatnamSS . Effect of oxytocics on prostaglandin levels in the third stage of labour. Gynecologic and Obstetric Investigation1990;29(3):177‐80. ">Ilancheran 1990</a>; <a href="./references#CD005456-bbs2-0006" title="JolivetA , RobynC , Huraux‐RenduC , GautrayJP . Effect of ergot alkaloid derivatives on milk secretion in the immediate postpartum period. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction1978;7(1):129‐34. ">Jolivet 1978</a>; <a href="./references#CD005456-bbs2-0007" title="KerekesL , DomokosN . The effect of prostaglandin F2alpha on third stage labour. Prostaglandins1979;18:161‐6. ">Kerekes 1979</a>; <a href="./references#CD005456-bbs2-0008" title="McGintyLB . A study of the vasopressor effects of oxytocics when used intravenously in the third stage of labour. Western Journal of Surgery1956;64:22‐8. ">McGinty 1956</a>) (<a href="#CD005456-fig-0002">Figure 2</a>; <a href="#CD005456-fig-0003">Figure 3</a>). </p> <p>For the main comparison, ergot alkaloids versus no uterotonic agents, the quality of the evidence for the outcomes ranged from very low to moderate (see <a href="./full#CD005456-tbl-0001">summary of findings Table for the main comparison</a>). The quality of the evidence for mean blood loss was moderate; there were limitations in the study design, which gave us reason to downgrade our assessment of the evidence. The quality of evidence for moderate PPH and severe PPH was low and very low. We downgraded our quality assessments for PPH due to there being limitations in study design, inconsistency in results, and imprecision. Only one study contributed to the evidence for maternal haemoglobin level 24 to 48 hours postpartum, and pain after birth requiring the need for analgesia. We assessed the quality of evidence for these outcomes as moderate, due to limitations in study design. We also noted limitations in study design and inconsistency among the studies contributing to the evidence for the use of therapeutic uterotonics and elevation of blood pressure, so we judged the quality of evidence as low. The quality of the evidence for the comparison of intravenous/intramuscular ergot alkaloids versus no uterotonic agents was similar to the main comparison of administration by any route, but most of the studies (seven of eight) used the intravenous/intramuscular route (see <a href="./full#CD005456-tbl-0002">summary of findings Table 2</a>). Only one small study (289 women) compared oral ergometrine with placebo and it showed no benefit of ergometrine over placebo. We judged the quality of this evidence to be low for all outcomes; we downgraded our assessment because of imprecision due to the evidence coming from a single study with a small sample size and wide confidence intervals (see <a href="./full#CD005456-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD005456-sec-0112"> <h3 class="title" id="CD005456-sec-0112">Potential biases in the review process</h3> <p>The possibility of introducing bias was present at every stage of the review process. In order to minimise bias, two review authors independently assessed studies for eligibility, undertook data extraction and carried out GRADE quality assessments. We undertook a comprehensive search strategy in order to minimise the potential for publication bias. We also reassessed previously excluded studies to ensure they had not been excluded due to not reporting outcomes of interest in order to avoid outcome reporting bias. </p> </section> <section id="CD005456-sec-0113"> <h3 class="title" id="CD005456-sec-0113">Agreements and disagreements with other studies or reviews</h3> <p>To date, there are no other published systematic reviews comparing ergot alkaloids to no uterotonics. Two Cochrane Reviews compared oxytocin versus no uterotonics or any uterotonics including ergot alkaloids (<a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>), or ergot alkaloids plus oxytocin versus oxytocin (<a href="./references#CD005456-bbs2-0090" title="McDonaldS , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201.pub2] ">McDonald 2004</a>). </p> <p>The effects found in this review, of ergot alkaloids administered in the third stage of labour on reduction of moderate PPH and use of therapeutic uterotonics (when compared with no uterotonics), were similar to the findings of the oxytocin review by Westhoff and colleagues (<a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>). A lower mean blood loss was noted in our review, but it was not identified in any study included in <a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>. No difference in the rate of manual removal of the placenta was noted in our review which is in accordance with the Cochrane Reviews on oxytocin, misoprostol, or syntometrine versus no uterotonic agents or other uterotonics (<a href="./references#CD005456-bbs2-0090" title="McDonaldS , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201.pub2] ">McDonald 2004</a>; <a href="./references#CD005456-bbs2-0096" title="TunçalpÖ , HofmeyrGJ , GülmezogluAM . Prostaglandins for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD000494.pub4] ">Tunçalp 2012</a>; <a href="./references#CD005456-bbs2-0099" title="WesthoffG , CotterAM , TolosaJE . Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD001808.pub2] ">Westhoff 2013</a>). The combination of 5 IU of oxytocin plus 0.5 mg of ergot alkaloids (syntometrine) showed a greater reduction of the risk of moderate PPH and therapeutic uterotonics compared with 10 IU of oxytocin, but the risks of elevation of diastolic blood pressure, vomiting, nausea and combined vomiting and nausea were reported (<a href="./references#CD005456-bbs2-0090" title="McDonaldS , AbbottJM , HigginsSP . Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD000201.pub2] ">McDonald 2004</a>). The adverse effects associated with syntometrine may be due to higher doses of ergot alkaloids in the combination. </p> <p>One recently published network meta‐analysis (NMA), <a href="./references#CD005456-bbs2-0084" title="GallosID , WilliamsHM , PriceMJ , MerrielA , GeeH , LissauerD , et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis. Cochrane Database of Systematic Reviews2018, Issue 4. [DOI: 10.1002/14651858.CD011689.pub2] ">Gallos 2018</a>, suggests that ergot alkaloids are also beneficial in terms of preventing PPH, though they appeared to be most effective when combined with oxytocin. The authors of this NMA concluded that 'ergometrine plus oxytocin combination, carbetocin, and misoprostol plus oxytocin combination were most effective for preventing PPH ≥ 500 mL than the current standard oxytocin. Ergometrine plus oxytocin combination was more effective for preventing PPH ≥ 1000 mL than oxytocin.' </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005456-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005456-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005456-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005456-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 1 Mean blood loss (mL)." data-id="CD005456-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 1 Mean blood loss (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 2 Estimated or measured blood loss of at least 500 mL." data-id="CD005456-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 2 Estimated or measured blood loss of at least 500 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 3 Estimated or measured blood loss of at least 1000 mL." data-id="CD005456-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 3 Estimated or measured blood loss of at least 1000 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 4 Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL)." data-id="CD005456-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 4 Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 5 Blood transfusion." data-id="CD005456-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 5 Blood transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 6 Use of therapeutic uterotonics." data-id="CD005456-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 6 Use of therapeutic uterotonics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 7 Length of third stage of labour (minutes)." data-id="CD005456-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 7 Length of third stage of labour (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 8 Retained placenta or manual removal of placenta, or both." data-id="CD005456-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 8 Retained placenta or manual removal of placenta, or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 9 Vomiting." data-id="CD005456-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 9 Vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 10 Nausea." data-id="CD005456-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 10 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 11 Elevation of blood pressure." data-id="CD005456-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 11 Elevation of blood pressure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 12 Pain after birth requiring analgesia (not prespecified)." data-id="CD005456-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 12 Pain after birth requiring analgesia (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 13 Headache (not prespecified)." data-id="CD005456-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 13 Headache (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 14 Eclamptic fit (not prespecified)." data-id="CD005456-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 14 Eclamptic fit (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 15 Uterine subinvolution at routine follow up (not prespecified)." data-id="CD005456-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 15 Uterine subinvolution at routine follow up (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 16 Postpartum febrile morbidity (not prespecified)." data-id="CD005456-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 16 Postpartum febrile morbidity (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 17 Postnatal haemoglobin &lt; 10 g/dL (not prespecified)." data-id="CD005456-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Ergot alkaloids (any route of administration) versus no uterotonic agents, Outcome 17 Postnatal haemoglobin &lt; 10 g/dL (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 1 Mean blood loss (mL)." data-id="CD005456-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 1 Mean blood loss (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 2 Estimated or measured blood loss of at least 500 mL." data-id="CD005456-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 2 Estimated or measured blood loss of at least 500 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 3 Estimated or measured blood loss of at least 1000 mL." data-id="CD005456-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 3 Estimated or measured blood loss of at least 1000 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 4 Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL)." data-id="CD005456-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 4 Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 5 Blood transfusion." data-id="CD005456-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 5 Blood transfusion. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 6 Use of therapeutic uterotonics." data-id="CD005456-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 6 Use of therapeutic uterotonics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 7 Length of third stage of labour (minutes)." data-id="CD005456-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 7 Length of third stage of labour (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 8 Retained placenta or manual removal of placenta, or both." data-id="CD005456-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 8 Retained placenta or manual removal of placenta, or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 9 Vomiting." data-id="CD005456-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 9 Vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 10 Nausea." data-id="CD005456-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 10 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 11 Elevation of blood pressure." data-id="CD005456-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 11 Elevation of blood pressure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 12 Pain after birth requiring analgesia (not prespecified)." data-id="CD005456-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 12 Pain after birth requiring analgesia (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 13 Headache (not prespecified)." data-id="CD005456-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 13 Headache (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 14 Eclamptic fit (not prespecified)." data-id="CD005456-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 14 Eclamptic fit (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 15 Uterine subinvolution at routine follow up (not prespecified)." data-id="CD005456-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 15 Uterine subinvolution at routine follow up (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 16 Postpartum febrile morbidity (not prespecified)." data-id="CD005456-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 16 Postpartum febrile morbidity (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 17 Postnatal haemoglobin &lt; 10 g/dL (not prespecified)." data-id="CD005456-fig-0037" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Intravenous/intramuscular ergot alkaloids versus no uterotonic agents, Outcome 17 Postnatal haemoglobin &lt; 10 g/dL (not prespecified). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 1 Mean blood loss (mL)." data-id="CD005456-fig-0038" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 1 Mean blood loss (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 2 Estimated or measured blood loss of at least 500 mL." data-id="CD005456-fig-0039" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 2 Estimated or measured blood loss of at least 500 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 3 Estimated or measured blood loss of at least 1000 mL." data-id="CD005456-fig-0040" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 3 Estimated or measured blood loss of at least 1000 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 4 Blood transfusion." data-id="CD005456-fig-0041" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 4 Blood transfusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 5 Use of therapeutic uterotonics." data-id="CD005456-fig-0042" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 5 Use of therapeutic uterotonics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 6 Retained placenta or manual removal of placenta, or both." data-id="CD005456-fig-0043" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Oral ergot alkaloids versus no uterotonic agents, Outcome 6 Retained placenta or manual removal of placenta, or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents, Outcome 1 Mean blood loss (mL)." data-id="CD005456-fig-0044" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents, Outcome 1 Mean blood loss (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents, Outcome 2 Estimated or measured blood loss of at least 500 mL." data-id="CD005456-fig-0045" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents, Outcome 2 Estimated or measured blood loss of at least 500 mL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents, Outcome 3 Length of third stage of labour (minutes)." data-id="CD005456-fig-0046" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents, Outcome 3 Length of third stage of labour (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005456-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/urn:x-wiley:14651858:media:CD005456:CD005456-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_t/tCD005456-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents, Outcome 4 Retained placenta or manual removal of placenta, or both." data-id="CD005456-fig-0047" src="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents, Outcome 4 Retained placenta or manual removal of placenta, or both. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/media/CDSR/CD005456/image_n/nCD005456-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005456-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ergot alkaloids (any route of administration) versus no uterotonic agents in the third stage of labour</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ergot alkaloids (any route of administration) versus no uterotonic agents in the third stage of labour</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Settings:</b> hospital settings in the USA, Ireland, and the Netherlands<br/> <b>Intervention:</b> ergot alkaloids (any route of administration) </p> <p><b>Comparison</b>: no uterotonic agents </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ergot alkaloids (any routes) and no uterotonic agents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean blood loss (mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss ranged across control groups from 234.8 to 520 mL</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss in the intervention groups was<br/> <b>80.52 mL lower</b><br/> (96.39 to 64.65 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2718<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>PPH (estimated or measured blood loss of at least 500 mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.52</b> <br/> (0.28 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3708<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><br/> (33 to 111) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/> (34 to 113) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Severe PPH (estimated or measured blood loss of at least 1000 mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.32</b> <br/> (0.04 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1718<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><br/> (1 to 80) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/> (3 to 166) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maternal haemoglobin concentration at 24 to 48 hours postpartum in the control group was 12.09 g/dL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maternal haemoglobin concentration at 24 to 48 hours postpartum in the intervention groups was<br/> <b>0.5 g/dL higher</b><br/> (0.38 to 0.62 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>1</sup><br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Use of therapeutic uterotonics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.37</b> <br/> (0.15 to 0.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2698<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b><br/> (20 to 119) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b><br/> (19 to 116) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Elevation of blood pressure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.6</b> <br/> (1.03 to 6.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2559<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b><br/> (137 to 874) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b><br/> (124 to 788) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Pain after birth requiring analgesia (not prespecified)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.53</b> <br/> (1.34 to 4.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<sup>1</sup><br/> <b>moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (24 to 86) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (24 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>PPH:</b> postpartum haemorrhage; <b>mL</b> : millilitre; <b>g/dL</b>: grams per decilitre </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Limitations in study design (‐1) </p> <p>2 Inconsistency of results, high I<sup>2</sup> value (‐1) </p> <p><sup>3</sup> Wide confidence interval crossing the line of no effect (‐1) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Ergot alkaloids (any route of administration) versus no uterotonic agents in the third stage of labour</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005456-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous/intramuscular ergot alkaloids versus no uterotonic agents in the third stage of labour</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous/intramuscular ergot alkaloids versus no uterotonic agents in the third stage of labour</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Settings:</b> hospital settings in USA and Ireland<br/> <b>Intervention:</b> intravenous/intramuscular ergot alkaloids </p> <p><b>Comparison</b>: no uterotonic agents </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intravenous/intramuscular ergot alkaloids versus no uterotonic agents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean blood loss (mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss ranged across control groups from 234.8 to 325.9 mL</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss in the intervention groups was<br/> <b>81.75 mL lower</b><br/> (97.88 to 65.61 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2429<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Estimated or measured blood loss of at least 500 mL</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.41</b> <br/> (0.22 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3419<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 1000</b><br/> (21 to 72) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (18 to 62) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Estimated or measured blood loss of at least 1000 mL</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.09</b> <br/> (0.01 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/> (0 to 11) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/> (0 to 11) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maternal haemoglobin concentration at 24 to 48 hours postpartum in the control group was 12.09 g/dL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean maternal haemoglobin concentration at 24 to 48 hours postpartum in the intervention groups was<br/> <b>0.5 g/dL higher</b><br/> (0.38 to 0.62 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Use of therapeutic uterotonics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.25</b> <br/> (0.1 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2409<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><br/> (13 to 83) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b><br/> (13 to 83) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Elevation of blood pressure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.6</b> <br/> (1.03 to 6.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2559<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>346 per 1000</b><br/> (137 to 874) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b><br/> (124 to 788) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Pain after birth requiring analgesia (not prespecified)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.53</b> <br/> (1.34 to 4.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1429<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (24 to 86) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 1000</b><br/> (24 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>PPH:</b> postpartum haemorrhage; <b>mL</b> : millilitre; <b>g/dL</b>: grams per decilitre </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Limitations in study design (‐1) </p> <p><sup>2</sup> Inconsistency of results, high I<sup>2</sup> value (‐1) </p> <p><sup>3</sup> Single study with few events (‐1) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous/intramuscular ergot alkaloids versus no uterotonic agents in the third stage of labour</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005456-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral ergot alkaloids versus no uterotonic agents in the third stage of labour</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral ergot alkaloids versus no uterotonic agents in the third stage of labour</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women in the third stage of labour<br/> <b>Settings:</b> a single study, hospital setting in the Netherlands<br/> <b>Intervention:</b> oral ergot alkaloids </p> <p><b>Comparison</b>: no uterotonic agents </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral ergot alkaloids versus no uterotonic agents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean blood loss (mL)</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss in the control group was 520 mL</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean blood loss in the intervention groups was<br/> <b>44 mL lower</b><br/> (132.08 lower to 44.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Estimated or measured blood loss of at least 500 mL</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.96</b> <br/> (0.72 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>289<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>385 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b><br/> (277 to 497) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>385 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>370 per 1000</b><br/> (277 to 497) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Estimated or measured blood loss of at least 1000 mL</b><br/> visual estimation </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.36 to 1.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>289<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>112 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b><br/> (40 to 168) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>112 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>82 per 1000</b><br/> (40 to 168) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in the trial</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Use of therapeutic uterotonics</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.79</b> <br/> (0.47 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>289<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/> (86 to 244) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/> (86 to 244) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Elevation of blood pressure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in the trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain after birth requiring analgesia (not prespecified)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported in the trial</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>PPH:</b> postpartum haemorrhage; <b>mL</b> : millilitre; <b>g/dL</b>: grams per decilitre </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Single study with small sample size and wide confidence interval (‐2) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral ergot alkaloids versus no uterotonic agents in the third stage of labour</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/full#CD005456-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005456-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ergot alkaloids (any route of administration) versus no uterotonic agents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean blood loss (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐80.52 [‐96.39, ‐64.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Estimated or measured blood loss of at least 500 mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.28, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Estimated or measured blood loss of at least 1000 mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.04, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.38, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Use of therapeutic uterotonics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.15, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Length of third stage of labour (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐3.33, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Retained placenta or manual removal of placenta, or both <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.86 [0.36, 41.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.82 [0.37, 126.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.63 [0.26, 284.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Elevation of blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [1.03, 6.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Pain after birth requiring analgesia (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.34, 4.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Headache (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.93 [0.51, 30.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Eclamptic fit (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.34 [0.38, 29.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Uterine subinvolution at routine follow up (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.56, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Postpartum febrile morbidity (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.34, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Postnatal haemoglobin &lt; 10 g/dL (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.14, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ergot alkaloids (any route of administration) versus no uterotonic agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005456-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intravenous/intramuscular ergot alkaloids versus no uterotonic agents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean blood loss (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐81.75 [‐97.88, ‐65.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Estimated or measured blood loss of at least 500 mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.22, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Estimated or measured blood loss of at least 1000 mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Maternal haemoglobin concentration at 24 to 48 hours postpartum (g/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.38, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.05, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Use of therapeutic uterotonics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.10, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Length of third stage of labour (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐3.33, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Retained placenta or manual removal of placenta, or both <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [0.14, 99.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.82 [0.37, 126.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.63 [0.26, 284.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Elevation of blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [1.03, 6.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Pain after birth requiring analgesia (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.34, 4.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Headache (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.93 [0.51, 30.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Eclamptic fit (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.34 [0.38, 29.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Uterine subinvolution at routine follow up (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.56, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Postpartum febrile morbidity (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.34, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Postnatal haemoglobin &lt; 10 g/dL (not prespecified) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.14, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intravenous/intramuscular ergot alkaloids versus no uterotonic agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005456-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral ergot alkaloids versus no uterotonic agents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean blood loss (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐44.0 [‐132.08, 44.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Estimated or measured blood loss of at least 500 mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.72, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Estimated or measured blood loss of at least 1000 mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.36, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Use of therapeutic uterotonics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.47, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Retained placenta or manual removal of placenta, or both <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.90 [0.24, 101.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7 Elevation of blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8 Pain after birth requiring analgesia (not prespecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral ergot alkaloids versus no uterotonic agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005456-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mean blood loss (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐84.07 [‐102.47, ‐65.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Estimated or measured blood loss of at least 500 mL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.16, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Length of third stage of labour (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.07 [‐2.32, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Retained placenta or manual removal of placenta, or both <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.79 [2.40, 68.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis based on trial quality comparing ergot alkaloids (any routes) and no uterotonic agents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005456.pub3/references#CD005456-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005456.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005456-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005456-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005456-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD005456-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD005456-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005456-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005456-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005456\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005456\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005456\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005456\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005456\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mvgXlmVk&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005456.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005456.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005456.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005456.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005456.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719648603"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005456.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719648606"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005456.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dede06be79371',t:'MTc0MDcxOTY0OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 